[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 857
1. Tauchmanovà L, Pivonello R, Di Somma C, Rossi R, De Martino MC, Camera L, Klain M, Salvatore M, Lombardi G, Colao A: Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab; 2006 May;91(5):1779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status.
  • Cushing's disease and adrenal and ectopic Cushing's syndrome.
  • MATERIALS AND METHODS: Eighty consecutive patients and 80 controls were prospectively enrolled: 37 patients (21 females) with pituitary ACTH-secreting adenoma, 18 (14 females) with adrenocortical adenoma, 15 (11 females) with adrenal carcinoma of mixed secretion, and 10 (three females) with ectopic ACTH secretion.
  • At diagnosis, bone mineral density (BMD) was determined by the dual-energy x-ray absorptiometry technique at the lumbar spine (L1-L4) and femoral neck; vertebral fractures were investigated by standard spinal radiographs.
  • [MeSH-minor] Adenoma / blood. Adolescent. Adrenal Gland Neoplasms / blood. Adrenocorticotropic Hormone / blood. Adult. Aged. Biomarkers. Body Mass Index. Carcinoma / blood. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Male. Middle Aged. Prospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522701.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


2. Müssig K, Wehrmann M, Horger M, Teichmann R, Maser-Gluth C, Häring HU, Overkamp D: Steroid profile in an adrenocortical carcinoma producing aldosterone. Exp Clin Endocrinol Diabetes; 2005 Apr;113(4):236-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid profile in an adrenocortical carcinoma producing aldosterone.
  • We report a rare case of primary aldosteronism due to an adrenocortical carcinoma.
  • A 61-year-old woman with a history of hypertension and hypokalemia was referred for evaluation of a 4.2 cm measuring adrenal mass without secondary signs of malignancy.
  • The patient underwent surgical resection of the adrenal mass; histology revealed an adrenocortical carcinoma.
  • Four months after adrenalectomy, the patient presented again with hypokalemic hypertension and was found to have metastatic disease.
  • Careful hormonal investigation should be obtained in patients with adrenal masses causing excessive aldosterone secretion.
  • In uncertain cases of primary aldosteronism, we would suggest to measure 18-hydroxycortisol levels, as excessive amounts may indicate adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / blood. Adrenal Cortex Neoplasms / secretion. Aldosterone / secretion
  • [MeSH-minor] Adrenal Cortex Hormones / blood. Female. Humans. Middle Aged. Posture. Supine Position. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15891961.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 4964P6T9RB / Aldosterone
  •  go-up   go-down


3. Fariña LA, Antón I, Fernández GC: [Large adrenal pseudocyst mimicking cystic pheochromocytoma: excision minimising laparoscopic access]. Actas Urol Esp; 2009 Sep;33(8):913-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large adrenal pseudocyst mimicking cystic pheochromocytoma: excision minimising laparoscopic access].
  • [Transliterated title] Seudoquiste adrenal grande que simula feocromocitoma quístico: exéresis minimizando el acceso laparoscópico.
  • INTRODUCTION: Adrenal cysts and pseudocysts are rare and usually benign and asymptomatic; they are discovered either accidentally or during examination for non-specific abdominal discomfort.
  • The differential diagnosis for adrenal cysts must consider cystic adrenal carcinoma and cystic pheochromocytoma, which are both extremely rare, but more severe and difficult to treat.
  • PATIENTS AND RESULTS: A 55 year-old woman reported right-side flank pain; imaging studies discovered a 10 cm cystic adrenal tumour, with radiological indications of cystic pheochromocytoma.
  • CONCLUSIONS: As less invasive laparoscopic procedures become widespread, an increasing number of case reports and series of cases regarding adrenal cyst operations have recently been reported.
  • A review of the literature shows that the cysts are generally benign, but it is not always possible to identify cystic adrenal carcinoma or cystic pheochromocytoma from the radiology image.
  • [MeSH-major] Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Adrenal Gland Neoplasms / diagnosis. Cysts / diagnosis. Cysts / surgery. Laparoscopy. Pheochromocytoma / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


Advertisement
4. Katsurago N, Shiraishi Y, Hashizume M, Miyasaka Y: [Long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer; report of a case]. Kyobu Geka; 2006 Feb;59(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer; report of a case].
  • We describe a case of long-term survival following multimodality treatment of metachronous metastases (parotid gland, adrenal gland, brain and mediastinal lymph node) after resection of non-small cell lung cancer.
  • A 72-year-old man had a past history of right upper lobectomy for pT3N0M0 tubular adenocarcinoma of the lung 12 years ago and left lower lobectomy for pT3N1M0 papillary adenocarcinoma of the lung 42 months ago, and left parotidectomy and irradiation to the neck for parotid metastasis 20 months ago.
  • A progressive increase in serum CEA level during the follow-up period revealed a 5 cm left adrenal mass and small (1 cm or less) multiple brain metastases, and a 2 cm mediastinal lymph node.
  • We confirm the possibility of long-term survival following multimodality treatment even though multiple organ metastases were found after resection of non-small cell lung cancer.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Brain Neoplasms / secondary. Brain Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Parotid Neoplasms / secondary. Parotid Neoplasms / therapy


5. Koschker AC, Fassnacht M, Hahner S, Weismann D, Allolio B: Adrenocortical carcinoma -- improving patient care by establishing new structures. Exp Clin Endocrinol Diabetes; 2006 Feb;114(2):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma -- improving patient care by establishing new structures.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare and highly malignant tumour with a poor prognosis.
  • DIAGNOSIS: In case of an adrenal mass, hormonal workup before surgery is required for differential diagnosis, perioperative management, and for follow-up.
  • GANIMED, as a Germany-wide network of experts on adrenal diseases, has been founded allowing for improved gathering of data and joint studies.
  • ENSAT (European Network for the Study of Adrenal Tumours) has been brought to life, aiming at European standards for therapy, diagnosis and tumour banking.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / surgery
  • [MeSH-minor] Adrenalectomy. Clinical Trials as Topic. Diagnosis, Differential. Humans. Mutation. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570232.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 24
  •  go-up   go-down


6. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J: Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res; 2010 Nov 1;70(21):8276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers.
  • Adrenocortical carcinoma (ACC) is a rare disease with an overall poor but heterogeneous prognosis.
  • [MeSH-major] Adrenocortical Carcinoma / genetics. Biomarkers, Tumor / genetics. Gene Expression Profiling. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. beta Catenin / genetics


7. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, Sanders D, Thomas DG, Doherty G, Hammer G: Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res; 2009 Jan 15;15(2):668-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling.
  • PURPOSE: Our understanding of adrenocortical carcinoma (ACC) has improved considerably, yet many unanswered questions remain.
  • EXPERIMENTAL DESIGN: We did a whole genome gene expression study of a large cohort of adrenocortical tissues annotated with clinicopathologic data.
  • Using Affymetrix Human Genome U133 Plus 2.0 oligonucleotide arrays, transcriptional profiles were generated for 10 normal adrenal cortices (NC), 22 adrenocortical adenomas (ACA), and 33 ACCs.
  • RESULTS: The overall classification of adrenocortical tumors was recapitulated using principal component analysis of the entire data set.
  • Cluster analysis of the ACCs revealed two subtypes that reflected tumor proliferation, as measured by mitotic counts and cell cycle genes.
  • CONCLUSIONS: This study lays the foundation for the molecular classification and prognostication of adrenocortical tumors and also provides a rich source of potential diagnostic and prognostic markers.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1039-45 [10514385.001]
  • [Cites] World J Surg. 2004 Sep;28(9):896-903 [15593464.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):579-83 [15920519.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6646-56 [16007166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5079-90 [17075127.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):632-41 [17082810.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D760-5 [17099226.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):1-12 [17237261.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2007 Mar;115(3):175-8 [17427106.001]
  • [Cites] APMIS. 2007 Apr;115(4):381-4 [17504308.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):345-54 [17525483.001]
  • [Cites] Endocr Pathol. 2006 Winter;17(4):355-63 [17525484.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Oct;4(10):591-602 [17898809.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):425-31 [18281524.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Apr;93(4):1442-9 [18198226.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):145-52 [10824999.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Endocr Pathol. 2001 Winter;12(4):397-406 [11914473.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74 [12107267.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6810-8 [14555994.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):809-17 [15191351.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4219-23 [8797595.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] J Mol Endocrinol. 1999 Aug;23(1):23-32 [10425444.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • (PMID = 19147773.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA046592-209023; United States / NCI NIH HHS / CA / CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / 5 P30 CA46592; United States / NCI NIH HHS / CA / CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-219023; United States / NCI NIH HHS / CA / P30 CA046592-199023; United States / NCI NIH HHS / CA / P30 CA046592-209023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin E
  • [Other-IDs] NLM/ NIHMS78831; NLM/ PMC2629378
  •  go-up   go-down


8. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, Bartsch DK: Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol; 2006 Apr;154(4):587-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors.
  • OBJECTIVES: Adrenocortical carcinoma (ACC) is a rare malignant neoplasm with extremely poor prognosis.
  • The molecular mechanisms of adrenocortical tumorigenesis are still not well understood.
  • The comparative analysis by cDNA microarrays of gene-expression patterns of benign and malignant adrenocortical tumors allows us to identify new tumor-suppressor genes and proto-oncogenes underlying adrenocortical tumorigenesis.
  • DESIGN AND METHODS: Total RNA from fresh-frozen tissue of 10 ACC and 10 benign adrenocortical adenomas was isolated after histologic confirmation of neoplastic cellularity of at least 85%.
  • The reference consisted of pooled RNA of 10 normal adrenal cortex samples.
  • RESULTS: The comparative analysis of gene expression revealed many genes with more than fourfold expression difference between ACC and normal tissue (42 genes), cortical adenoma and normal tissue (11 genes), and ACC and cortical adenoma (21 genes) respectively.
  • As confirmed by real-time PCR, the IGF2 gene was significantly upregulated in ACCs versus cortical adenomas and normal cortical tissue.
  • Genes that were downregulated in adrenocortical tumors included chromogranin B and early growth response factor 1.
  • CONCLUSIONS: Comprehensive expression profiling of adrenocortical tumors by the cDNA microarray technique is a very powerful tool to elucidate the molecular steps associated with the tumorigenesis of these ill-defined neoplasms.

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556722.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


9. Costa MH, Latronico AC, Martin RM, Barbosa AS, Almeida MQ, Lotfi CF, Valassi HP, Nishi MY, Lucon AM, Siqueira SA, Zerbini MC, Carvalho LR, Mendonca BB, Fragoso MC: Expression profiles of the glucose-dependent insulinotropic peptide receptor and LHCGR in sporadic adrenocortical tumors. J Endocrinol; 2009 Feb;200(2):167-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiles of the glucose-dependent insulinotropic peptide receptor and LHCGR in sporadic adrenocortical tumors.
  • Aberrant expression of these receptors has rarely been demonstrated in adult sporadic adrenocortical tumors with a lack of data on pediatric tumors.
  • We quantified the GIPR and LHCGR expression in a large cohort of 55 patients (25 children and 30 adults) with functioning and non-functioning sporadic adrenocortical tumors.
  • Thirty-eight tumors were classified as adenomas whereas 17 were carcinomas.
  • Mean expression values were determined by fold increase in comparison with a normal adrenal pool.
  • GIPR mRNA levels were significantly higher in adrenocortical carcinomas than in adenomas from both pediatric and adult groups.
  • LHCGR expression was similar in both carcinomas and adenomas from the pediatric group but significantly lower in carcinomas than in adenomas from the adult group (median 0.06 and 2.3 respectively, P<0.001).
  • Staining and real-time PCR results correlated positively only when GIPR mRNA levels were increased at least two-fold in comparison with normal adrenal expression levels.
  • In conclusion, GIPR overexpression was observed in pediatric and adult adrenocortical tumors and very low levels of LHCGR expression were found in all adult adrenocortical carcinomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Adenoma / genetics. Adrenocortical Carcinoma / genetics. Gene Expression Regulation, Neoplastic / genetics. Receptors, Gastrointestinal Hormone / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18971217.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Gastrointestinal Hormone; 0 / Receptors, LH; 0 / gastric inhibitory polypeptide receptor
  •  go-up   go-down


10. Pradeep PV, Mishra AK, Aggarwal V, Bhargav PR, Gupta SK, Agarwal A: Adrenal cysts: an institutional experience. World J Surg; 2006 Oct;30(10):1817-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal cysts: an institutional experience.
  • INTRODUCTION: Adrenal cysts are rare clinical entities.
  • We report our institutional experience with adrenal cysts and also assess various management options.
  • MATERIAL AND METHODS: Over the past 15 years the Department of Endocrine Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, has had seven cases of adrenal cysts, of which two were functional: one patient had Cushing's syndrome and the other patient had pheochromocytoma.
  • It is generally agreed that a hormonal work-up is necessary in all cases of adrenal cysts to rule out a sub-clinical disease.
  • Adrenal neoplasms, including adrenocortical carcinomas, can be associated with cysts that are benign in appearance.
  • However, surgical excision provides a definite histopathological diagnosis and also removes the fear of future complications such as hemorrhage into the cyst and local pressure effects due to the tumor.
  • CONCLUSIONS: Given that the adrenals are a vascular gland and taking into consideration the possibilities of bleeding and complications in the cyst, our treatment of choice is the elective excision of adrenal cysts.
  • [MeSH-major] Academies and Institutes / statistics & numerical data. Adrenal Gland Diseases / diagnosis. Adrenal Gland Diseases / surgery. Adrenalectomy / methods. Cysts / diagnosis. Cysts / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. India. Laparoscopy. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):915-7 [15711326.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):186-9 [4811049.001]
  • [Cites] J Urol. 1983 May;129(5):1031-3 [6854747.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1537-44 [15378490.001]
  • [Cites] Radiology. 1989 Oct;173(1):107-10 [2675177.001]
  • [Cites] J Endocrinol Invest. 1998 Feb;21(2):109-14 [9585385.001]
  • [Cites] Chirurgia (Bucur). 2004 Jul-Aug;99(4):255-8 [15560563.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):269-82 [6587703.001]
  • [Cites] Int Surg. 2005 Apr-Jun;90(2):78-80 [16119709.001]
  • [Cites] Ann Acad Med Singapore. 1999 Nov;28(6):863-6 [10672405.001]
  • [Cites] Am Surg. 1999 Feb;65(2):151-63 [9926751.001]
  • [Cites] Int Urol Nephrol. 1998;30(4):369-76 [9821036.001]
  • (PMID = 16983481.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Nader N, Raverot G, Emptoz-Bonneton A, Déchaud H, Bonnay M, Baudin E, Pugeat M: Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab; 2006 Jun;91(6):2165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Human hepatoma cell lines (HepG2), lacking estrogen receptor (ER)-alpha, and Hep89, stably transfected by ERalpha, were used.
  • PATIENTS AND OTHER PARTICIPANTS: The study included 10 male patients with recurrent adrenal carcinoma, receiving mitotane (4-6.5 g daily) for more than 6 months.
  • In the HepG2 cell line, 17beta-estradiol (E2) or o,p'-DDD treatment had no effect on mRNA or SHBG/CBG concentrations.
  • In contrast, in the Hep89 cell line, E2 increased concentrations of SHBG (r = 0.44, P < 0.0001) and CBG (r = 0.585, P < 0.0001) secreted into culture media in a dose-dependent manner. o,p'-DDD significantly increased SHBG (150% vs. control, P < 0.05) and CBG (184% vs. control, P < 0.05) production by Hep89 cells, at a concentration of 2 x 10(-5) m.
  • [MeSH-minor] Adrenal Gland Neoplasms / blood. Adrenal Gland Neoplasms / drug therapy. Estradiol / pharmacology. Estrogen Receptor alpha / drug effects. Estrogen Receptor alpha / physiology. Humans. Liver / metabolism. Male. Promoter Regions, Genetic. RNA, Messenger / analysis. Transcription, Genetic. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16551731.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Receptor alpha; 0 / RNA, Messenger; 0 / Sex Hormone-Binding Globulin; 4TI98Z838E / Estradiol; 78E4J5IB5J / Mitotane; 9010-38-2 / Transcortin
  •  go-up   go-down


12. van Hest LP, Ruijs MW, Wagner A, van der Meer CA, Verhoef S, van't Veer LJ, Meijers-Heijboer H: Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam Cancer; 2007;6(3):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Li-Fraumeni syndrome (LFS) is an autosomal dominantly inherited cancer predisposition syndrome characterized by a combination of tumors including sarcoma, breast cancer, brain tumors, adrenocortical carcinoma and leukemia.

  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 1996 Sep 1;24(17):3439-52 [8811101.001]
  • [Cites] Science. 1994 Jul 15;265(5170):346-55 [8023157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963-7 [7732013.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):176-81 [12619103.001]
  • [Cites] Hum Mutat. 1997;9(2):157-63 [9067756.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):313-20 [12619118.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1606-11 [7706467.001]
  • [Cites] Nat Genet. 1995 Jun;10(2):175-80 [7663512.001]
  • [Cites] Mol Biol Rep. 1994 Jan;19(1):23-9 [8170465.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jul 1;112(1):9-14 [10432928.001]
  • [Cites] Genome Biol. 2002;3(12):RESEARCH0079 [12537568.001]
  • [Cites] Oncogene. 1997 Aug 28;15(9):1059-67 [9285560.001]
  • [Cites] Oncogene. 1994 Feb;9(2):603-9 [8290271.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Hum Mutat. 2005 Jan;25(1):6-17 [15580553.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):278-82 [10362336.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):3970-8 [10435620.001]
  • [Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]
  • (PMID = 17318340.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


13. Li F, Zhong Z, Li R, Huang H, Wang L, Zheng D, Zhang D: [Expression and clinicopathologic significance of human achaete-scute homolog 1 in pulmonary neuroendocrine tumors]. Zhongguo Fei Ai Za Zhi; 2010 Apr;13(4):317-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: Human achaete-scute homolog 1 (hASH1) gene plays a critical role in development of the central nervous system, automatic nervous system, adrenal medullary chromaffin cells, thyroid C cells and pulmonary neuroendocrine cells.
  • METHODS: hASH1, Chromogranin A, Synaptophysin and CD56 expression were examined in lung tumor specimens (lung inflammatory pseudotumor, squamous cell carcinoma, adenocarcinomas, large cell carcinoma, typical carcinoids, atypical carcinoids, large cell neuroendocrine carcinomas and small cell lung carcinoma and corresponding normal lung specimens) using immunohistochemistry (S-P method).
  • Western blot and reverse transcription polymerase chain reaction (RT-PCR) assay were applied to detect the expressions of hASH1 protein and mRNA in lung cancer tissues.
  • RESULTS: hASH1 expression was positive in 2/16 (12.5%) typical carcinoids, 15/20 (75%) atypical carcinoids, 6/10 (60%) large cell neuroendocrine carcinomas and 31/40 (77.5%) small cell lung carcinoma, respectively, but not in any normal lung tissue (0/10), lung inflammatory pseudotumor (0/49), squamous cell carcinoma (0/30), adenocarcinomas (0/30) or large cell carcinoma (0/20).
  • There was a significant difference in hASH1 expression between typical carcinoids and atypical carcinoids (P < 0.01), but not in large cell neuroendocrine carcinomas and small cell lung carcinoma (P > 0.05).
  • CONCLUSION: hASH1 is a new kind of highly specific markers of pulmonary neuroendocrine tumours, and may be applied to clinical pathology diagnosis of the pulmonary neuroendocrine tumors.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Neuroendocrine / genetics. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Neuroendocrine / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Gene Expression Regulation, Neoplastic / genetics. Gene Expression Regulation, Neoplastic / physiology. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction. Small Cell Lung Carcinoma / genetics. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677557.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ASCL1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors
  •  go-up   go-down


14. Lee SE, Jeon EJ, Oh JH, Shim KH, Lee J, Kim EH, Choi SW, Min KO: [A case of advanced gastric cancer with perianal skin metastasis]. Korean J Gastroenterol; 2008 Jan;51(1):40-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with perianal skin metastasis].
  • The most common metastatic sites of gastric cancer are liver, lung, bone and adrenal gland.
  • However, skin metastases from gastric cancer are relatively rare.
  • We herein report a case of advanced gastric cancer with perianal skin metastasis in a 70-year-old male.
  • Endoscopy and abdominal CT scan demonstrated the stage IV gastric cancer.
  • He had one painless nodule on perianal skin area, biopsy of that lesion showed a feature of poorly differentiated adenocarcinoma clinically from the stomach.
  • We suspected that the perianal lesion was originated from gastric cancer.
  • [MeSH-major] Skin Neoplasms / diagnosis. Skin Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349561.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


15. Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE: Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Surgery; 2007 Dec;142(6):867-75; discussion 867-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
  • BACKGROUND: Adrenal cortical carcinoma (ACC) is a rare disease in which recurrence after surgery is common.
  • RESULTS: The median disease-free survival for all 186 patients was 12 months and the median overall survival (OS) was 37 months.
  • For patients with stable or responding disease to mitotane, the median OS from date of recurrence was 18 months, compared with 9 months (P = .01) for those who progressed.
  • CONCLUSIONS: Patients with recurrent ACC who have stable or responding disease to mitotane have a more favorable prognosis than those who progress.
  • Mitotane should be considered in most patients with recurrent ACC, including as preoperative therapy for those with recurrent disease considered for surgical resection.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063070.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


16. Advani A, Johnson SJ, Nicol MR, Papacleovoulou G, Evans DB, Vaikkakara S, Mason JI, Quinton R: Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma. Endocr J; 2010;57(7):651-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma.
  • Estrogen-secreting adrenal cancers are extremely rare, with feminizing symptoms attributed to aromatase expression in the adrenal tumor.
  • We describe a case of hypogonadotropic hypogonadism as a consequence of aberrant aromatase expression in a patient with adrenocortical adenocarcinoma.
  • A right adrenal mass was identified on CT scanning and the patient underwent an open adrenalectomy.
  • Immunohistochemistry of the adrenal cancer confirmed aberrant expression of aromatase in most, although not all, carcinoma cells.
  • This case highlights that clinical features of feminizing adrenocortical carcinomas can be secondary to estrogen production by aberrantly transcribed and translated aromatase within the tumor.
  • The diagnosis of adrenocortical adenocarcinoma should be considered in men presenting with low testosterone and gonadotropins, particularly in the presence of feminizing features.
  • [MeSH-major] Adenocarcinoma / genetics. Adrenal Cortex Neoplasms / genetics. Aromatase / genetics. Hypogonadism / genetics
  • [MeSH-minor] Adult. Age of Onset. Gene Expression Regulation, Enzymologic / physiology. Gene Expression Regulation, Neoplastic / physiology. Genetic Predisposition to Disease. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Hypogonadism, isolated, hypogonadotropic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467160.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase
  •  go-up   go-down


17. Bagwan IN, Cook G, Mudan S, Wotherspoon A: Unusual presentation of metastatic adenocarcinoma. World J Surg Oncol; 2007;5:116
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of metastatic adenocarcinoma.
  • BACKGROUND: The most common tumours of the adrenal gland are adenoma, pheochromocytoma, adrenocortical carcinoma, and metastases.
  • Although the imaging features of these tumours are established, the imaging characteristics of uncommon adrenal masses are less well known.
  • In patients with extradrenal tumour, incidental discovery of an adrenal mass necessitates excluding the possibility of metastatic malignancy.
  • CASE PRESENTATION: A 52 year-old female was diagnosed with oesophageal adenocarcinoma and treated with oesophagectomy and adjuvant chemotherapy.
  • Sixteen months later on staging CT scan a 2 x 2 cm adrenal mass was detected, which increased in size over a period of time to 3 x 3 cm in size.
  • Adrenalectomy was performed and histological examination revealed metastatic adenocarcinoma within an adrenal adenoma.
  • CONCLUSION: The present case highlights the unusual behaviour of an oesophageal adenocarcinoma causing metastasis to an adrenocortical adenoma.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Esophageal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 2005 Dec;52(6):785-8 [16410674.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1624-33 [16518827.001]
  • [Cites] J Nucl Med. 2001 Dec;42(12):1795-9 [11752075.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] AJR Am J Roentgenol. 1996 Oct;167(4):891-2 [8819376.001]
  • [Cites] Surgery. 2004 Dec;136(6):1289-96 [15657589.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4924-9 [15914530.001]
  • (PMID = 17949483.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2100056
  •  go-up   go-down


18. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B, Terzolo M: Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol; 2010 Aug 10;28(23):e401-2; author reply e403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2009 Sep 20;27(27):4619-29 [19667279.001]
  • (PMID = 20567001.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


19. Grubbs E, Lee JE: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer; 2009 Dec 15;115(24):5847; author reply 5848
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • (PMID = 19827149.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


20. Geiss HK, Feldhues R, Niemann S, Nolte O, Rieker R: Landouzy septicemia (sepsis tuberculosa acutissima) due to Mycobacterium microti in an immunocompetent man. Infection; 2005 Oct;33(5-6):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the following, we describe the case of a previously healthy man who underwent laparotomy for suspected adrenal carcinoma.
  • No other pathogen could be isolated during the clinical course, which finally led to the diagnosis of Landouzy septicemia (sepsis tuberculosa acutissima).

  • MedlinePlus Health Information. consumer health - Mycobacterial Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258876.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Al-Brahim N, Asa S: Myelolipoma with adrenocortical adenoma: an unusual combination that can resemble carcinoma. Endocr Pathol; 2007;18(2):103-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelolipoma with adrenocortical adenoma: an unusual combination that can resemble carcinoma.
  • Myelolipoma is a benign tumor that occurs in the adrenal gland and rarely in extra-adrenal sites.
  • Commonly, it is diagnosed as an incidental finding.
  • However, some reports indicate synchronous occurrence with other lesions including adrenocortical carcinoma.
  • It has very rarely been reported to occur in association with adrenocortical adenoma.
  • In this paper, we report three cases of adrenal myelolipoma associated with adrenocortical adenoma; in all three patients, the radiological appearance resembled adrenocortical carcinoma.
  • These cases emphasize the importance of this combination as a pitfall in the correct diagnosis and management of patients with adrenal masses.
  • [MeSH-major] Adenoma / pathology. Adrenal Cortex Neoplasms / pathology. Carcinoma / pathology. Myelolipoma / pathology
  • [MeSH-minor] Adrenal Glands / pathology. Adrenalectomy. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Organ Size. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 Apr;53(4):241-5 [12675769.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):591-2 [15086292.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Dec;26(6):1220-2 [15541988.001]
  • [Cites] Arch Pathol Lab Med. 2005 Jun;129(6):e144-7 [15913443.001]
  • [Cites] Arch Anat Pathol (Paris). 1974 Jun;22(2):119-22 [4421886.001]
  • [Cites] Australas Radiol. 2004 Jun;48(2):107-13 [15230740.001]
  • [Cites] Eur J Radiol. 2002 Feb;41(2):95-112 [11809539.001]
  • [Cites] Am J Pathol. 1950 Mar;26(2):211-33 [15406252.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):736-7 [12033969.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jul;130(7):1049-52 [16831034.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Apr 1;134(1):77-80 [11996801.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):416-8 [15157212.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):838-43 [16819325.001]
  • [Cites] Int J Urol. 2004 May;11(5):326-8 [15147550.001]
  • [Cites] J Urol. 1995 Oct;154(4):1470 [7658561.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):725-9 [15363042.001]
  • (PMID = 17917001.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Fardella CE, Mosso LM, Carvajal CA: [Primary aldosteronism]. Rev Med Chil; 2008 Jul;136(7):905-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the cardiovascular system, aldosterone modifies endothelial and smooth muscle cell response, increasing cardiovascular risk in a blood pressure-independent way.
  • This ratio increases along with the severity of the hypertensive disease.
  • The diagnostic work up of PA should confirm the autonomy of aldosterone secretion from the renin-angiotensin system and should differentiate the clinical subtypes of the disease.
  • Other causes are familial hyperaldosteronism (FH) type I (glucocorticoid-remediable aldosteronism), FH-II (non glucocorticoid-remediable aldosteronism), primary adrenal hyperplasia and adrenal carcinoma.
  • This article reviews the prevalence, diagnosis and treatment of PA and also the clinical, biochemical and genetic characteristics of its different subtypes.
  • [MeSH-major] Aldosterone / metabolism. Hyperaldosteronism / diagnosis. Hypertension / etiology

  • Genetic Alliance. consumer health - Primary aldosteronism.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949169.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Chile
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; EC 3.4.23.15 / Renin
  • [Number-of-references] 61
  •  go-up   go-down


23. Bollag WB, Kent P, White S, Wilson MV, Isales CM, Calle RA: Phorbol ester increases mitochondrial cholesterol content in NCI H295R cells. Mol Cell Endocrinol; 2008 Dec 16;296(1-2):53-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Angiotensin II (AngII), the primary agonist of aldosterone secretion from adrenal glomerulosa cells, is known to induce cholesterol mobilization to mitochondria.
  • To determine PKC's involvement, human adrenocortical carcinoma cells were incubated with or without PKC-activating phorbol 12-myristate 13-acetate (PMA) and mitochondrial cholesterol content assayed.

  • MedlinePlus Health Information. consumer health - Cholesterol.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1989 Nov;10(4):496-518 [2558878.001]
  • [Cites] Am J Physiol. 1989 Jan;256(1 Pt 1):C89-95 [2521426.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jan 15;182(1):254-61 [1731785.001]
  • [Cites] Endocrinology. 1992 Apr;130(4):2230-6 [1547736.001]
  • [Cites] Endocrinology. 1993 Oct;133(4):1555-61 [8404594.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5677-84 [7588323.001]
  • [Cites] Endocr Rev. 1995 Oct;16(5):649-81 [8529575.001]
  • [Cites] Mol Cell Endocrinol. 1996 Apr 19;118(1-2):137-44 [8735599.001]
  • [Cites] Endocr Rev. 1996 Jun;17(3):269-88 [8771360.001]
  • [Cites] J Biol Chem. 1996 Oct 18;271(42):25971-5 [8824233.001]
  • [Cites] Mol Endocrinol. 1998 Jul;12(7):962-72 [9658401.001]
  • [Cites] Mol Cell Endocrinol. 1999 Aug 20;154(1-2):1-9 [10509794.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2544-50 [15774560.001]
  • [Cites] Cell Mol Life Sci. 2005 Oct;62(19-20):2305-16 [16143829.001]
  • [Cites] Trends Pharmacol Sci. 2006 Jun;27(6):317-23 [16678913.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):6046-55 [16973724.001]
  • [Cites] Mol Endocrinol. 2007 Mar;21(3):589-601 [16973755.001]
  • [Cites] Cell Signal. 2007 Aug;19(8):1633-42 [17537614.001]
  • [Cites] Biochem Biophys Res Commun. 1983 Oct 31;116(2):555-62 [6418161.001]
  • [Cites] Mol Cell Endocrinol. 2001 May 25;177(1-2):71-9 [11377822.001]
  • [Cites] Mol Endocrinol. 2001 Aug;15(8):1245-54 [11463850.001]
  • [Cites] Mol Cell Endocrinol. 2002 Jun 28;192(1-2):7-16 [12088862.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4399-411 [12414987.001]
  • [Cites] Mol Cell Endocrinol. 2003 Aug 29;206(1-2):113-22 [12943994.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4905-15 [12960096.001]
  • [Cites] J Lipid Res. 1978 Nov;19(8):1068-70 [731127.001]
  • [Cites] Biochem J. 1986 Jul 1;237(1):253-8 [3800878.001]
  • [Cites] Endocrinology. 1990 Sep;127(3):1436-43 [1696885.001]
  • (PMID = 18793695.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL070046-04; United States / NHLBI NIH HHS / HL / R01 HL070046; United States / NHLBI NIH HHS / HL / HL070046-02; United States / NHLBI NIH HHS / HL / HL070046-04; United States / NHLBI NIH HHS / HL / HL070046; United States / NHLBI NIH HHS / HL / HL070046-03; United States / NHLBI NIH HHS / HL / R01 HL070046-02; United States / NHLBI NIH HHS / HL / R01 HL070046-03; United States / NHLBI NIH HHS / HL / HL070046-01A1; United States / NHLBI NIH HHS / HL / R01 HL070046-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Phorbol Esters; 0 / Steroids; 11128-99-7 / Angiotensin II; 20839-06-9 / phorbol-12-myristate; 85637-73-6 / Atrial Natriuretic Factor; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ NIHMS81938; NLM/ PMC2645228
  •  go-up   go-down


24. Matsuyama S, Shimonishi T, Yoshimura H, Higaki K, Nasu K, Toyooka M, Aoki S, Watanabe K, Sugihara H: An autopsy case of granulocyte-colony-stimulating-factor-producing extrahepatic bile duct carcinoma. World J Gastroenterol; 2008 May 14;14(18):2924-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An autopsy case of granulocyte-colony-stimulating-factor-producing extrahepatic bile duct carcinoma.
  • A 79-year-old man was referred to this department due to the presence of extrahepatic bile duct carcinoma with a tumor at the left chest wall.
  • The lesion was suspected to be a metastasis of bile duct carcinoma to the left wall, however, computed tomography (CT) revealed no regional lymph node or liver metastases.
  • At the time of admission, the white blood cell count was 21460 cells/muL (neutrophils, 18240 cells/muL) and this elevated to 106040 before death.
  • An autopsy showed a poorly differentiated adenocarcinoma with sarcomatous change, which had slightly invaded into the pancreas around the bile duct, and was found in the distal bile duct with multiple metastases to the chest wall, lung, kidney, adrenal body, liver, mesentery, vertebra and mediastinal and para-aortic lymph nodes, without locoregional lymph node and liver metastasis.
  • The cancer cells showed positive immunohistochemical staining for anti-G-CSF antibody.
  • This is believed to be the first report of an extrahepatic bile duct carcinoma that produces G-CSF.
  • Since G-CSF-producing carcinoma and sarcomatous change of the biliary tract leads to poor prognosis, early diagnosis and treatment are needed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / metabolism. Bile Ducts, Extrahepatic / metabolism. Granulocyte Colony-Stimulating Factor / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Jpn. 1990 Dec;25(6):762-7 [1703976.001]
  • [Cites] Jpn J Clin Oncol. 1986 Mar;16(1):87-96 [3486302.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Jun;17(2):187-91 [9700579.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):273-5 [9934773.001]
  • [Cites] Surg Today. 2005;35(7):590-3 [15976958.001]
  • [Cites] J Gastroenterol. 2005 Dec;40(12):1158-9 [16378181.001]
  • [Cites] Int J Clin Oncol. 2006 Jun;11(3):246-9 [16850133.001]
  • [Cites] Gynecol Oncol. 2000 Sep;78(3 Pt 1):383-7 [10985899.001]
  • [Cites] Cell Tissue Res. 2000 Sep;301(3):353-67 [10994781.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):956-61 [11020857.001]
  • [Cites] Tumori. 2001 May-Jun;87(3):191-5 [11504376.001]
  • [Cites] Hepatogastroenterology. 2002 Nov-Dec;49(48):1751-4 [12397785.001]
  • [Cites] Hum Pathol. 2003 Dec;34(12):1337-44 [14691921.001]
  • [Cites] Int J Cell Cloning. 1985 Sep;3(5):294-303 [3900241.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1872-7 [7689920.001]
  • (PMID = 18473424.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC2710741
  •  go-up   go-down


25. Abadie C, Bernard F, Netchine I, Sanlaville D, Roque A, Rossignol S, Coupier I: Acute lymphocytic leukaemia in a child with Beckwith-Wiedemann syndrome harbouring a CDKN1C mutation. Eur J Med Genet; 2010 Nov-Dec;53(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This syndrome is a multigenic disorder caused by dysregulation of imprinted growth regulatory genes in the 11p15.5 region.
  • The most commonly reported tumours in this syndrome are tumours of embryologic origin such as Wilms tumours, hepatoblastomas, neuroblastomas, rhabdomyosarcomas and adrenocortical carcinomas.
  • We report the case of a 10-year-old patient diagnosed with BWS, harbouring a CDKN1C (p57(KIP2)) mutation, who developed a T-type acute lymphoblastic leukaemia.
  • We discuss the possibility of a link between BWS and leukaemia via one of the few known negative regulator of hematopoiesis, the transforming growth factor beta pathway, depending upon the up-regulation of CDKN1C.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / genetics. Cyclin-Dependent Kinase Inhibitor p57 / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20826236.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57
  •  go-up   go-down


26. Geller JL, Azer PC, Weiss LM, Mertens RB: Pigmented adrenocortical carcinoma: case report and review. Endocr Pathol; 2006;17(3):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pigmented adrenocortical carcinoma: case report and review.
  • Darkly pigmented adrenocortical neoplasms are rare tumors that are often referred to as "black adenomas," indicative of both their pigmented nature and their invariably benign clinical behavior in previously reported cases.
  • We herein describe an exceptional case of a malignant pigmented adrenocortical neoplasm, with late recurrence and metastasis.
  • At age 53, this female patient was diagnosed with Cushing's syndrome and underwent a laparoscopic right adrenalectomy, revealing a 3 cm well-circumscribed, darkly pigmented adrenocortical tumor.
  • The tumor exhibited several atypical histologic features and was diagnosed as an atypical pigmented adrenal cortical neoplasm of uncertain malignant potential.
  • Histologically, the tumor nodules were consistent with local recurrence/metastasis of the patient's previously excised pigmented adrenocortical neoplasm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Pigmentation. Retroperitoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1990 Apr 26;322(17):1195-201 [2325710.001]
  • [Cites] Am J Clin Pathol. 1987 Mar;87(3):334-41 [2435143.001]
  • [Cites] Hum Pathol. 1972 Sep;3(3):317-25 [5046900.001]
  • [Cites] Am J Clin Pathol. 1974 Jul;62(1):97-103 [4134750.001]
  • [Cites] Arch Pathol Lab Med. 1985 Feb;109(2):198-200 [3838445.001]
  • [Cites] CA Cancer J Clin. 1987 Nov-Dec;37(6):348-65 [3119168.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):265-80 [15163302.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1901-4 [15274373.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] J Natl Med Assoc. 2001 Jan;93(1):37-9 [12653379.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Am J Surg Pathol. 1998 May;22(5):603-14 [9591731.001]
  • [Cites] Mod Pathol. 1992 Jan;5(1):23-9 [1542635.001]
  • [Cites] Cancer. 1981 May 1;47(9):2153-61 [7226109.001]
  • [Cites] Arch Pathol Lab Med. 1991 Aug;115(8):813-5 [1863192.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):e125-8 [15387689.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):765-9 [2743269.001]
  • [Cites] Int J Surg Pathol. 2004 Jul;12(3):231-43 [15306935.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):766-73 [3967172.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 17308367.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Locali RF, Matsuoka PK, Cherbo T, Gabriel EA, Buffolo E: Renal and adrenal tumors with cardiac invasion: immediate surgical results in 14 patients. Arq Bras Cardiol; 2009 Mar;92(3):168-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal and adrenal tumors with cardiac invasion: immediate surgical results in 14 patients.
  • BACKGROUND: The resection of tumor thrombus of the inferior vena cava (IVC) and right atrium (RA) increases the survival rate of patients with renal/adrenal cancer.
  • OBJECTIVE: To evaluate the surgical procedure in cases of IVC and RA in the treatment of renal and adrenal tumors.
  • METHODS: Fourteen patients undergoing surgical intervention (during the period) between January 1997 and June 2007, for resection of IVC and/or RA thrombus due to renal or adrenal tumors, were retrospectively evaluated.
  • The patients (64.2% male) presented with Wilms' tumor, clear cell carcinoma and adrenal adenocarcinoma, and had mean age of 4.5, 60.5 and 2.5 years, respectively.
  • Two deaths, due to intraoperative cardiorespiratory arrest, were seen among patients with adrenal adenocarcinoma.
  • More postoperative complications are seen in patients with adrenal adenocarcinoma, and the postoperative prognosis is better for patients with Wilms' tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Heart Neoplasms / surgery. Kidney Neoplasms / pathology. Thrombectomy / methods. Vena Cava, Inferior. Venous Thrombosis / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adolescent. Adult. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Child, Preschool. Circulatory Arrest, Deep Hypothermia Induced / methods. Extracorporeal Circulation / methods. Female. Heart Atria / surgery. Humans. Infant. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Time Factors. Wilms Tumor / pathology. Wilms Tumor / surgery. Young Adult


28. Imataki O, Makimoto A, Kojima R, Sakiyama M, Hosono A, Takaue Y: Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int J Clin Oncol; 2006 Apr;11(2):156-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases.
  • Adrenocortical carcinoma is a rare malignancy in adolescents and young adults.
  • The prognosis of unresectable/metastatic adrenocortical carcinoma remains very poor because the rarity of the tumor has made it difficult to establish treatment guidelines, and diagnosis and the resultant treatment can be greatly delayed.
  • We treated a 24-year-old woman who was diagnosed with adrenocortical carcinoma of the right adrenal gland which extended to the inferior vena cava.
  • Although she underwent surgical resection of the extensive tumor as the primary treatment, the disease recurred in the lung and liver as multiple metastases shortly after surgery.
  • Finally, she underwent reduced-intensity allogeneic hematopoietic stem cell transplantation from an HLA 1-locus-mismatched sibling donor.
  • A prolonged survival of 39 months after the onset of the disease was achieved.
  • Although this experience is limited, we suggest that TIP chemotherapy was effective for adrenocortical carcinoma, and a graft-versus-tumor effect after reduced-intensity stem cell transplantation may have contributed to the prolonged survival.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Liver Neoplasms / therapy. Lung Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Graft vs Host Disease. Humans


29. Iwanami T, Uramoto H, Baba T, Takenaka M, Yokoyama E, Oka S, So T, Ono K, So T, Takenoyama M, Hanagiri T, Iwata T, Inoue M, Yasumoto K: [Treatment recommendations for adrenal metastasis of non-small cell lung cancer]. Kyobu Geka; 2010 Dec;63(13):1101-6; discussion 1106-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment recommendations for adrenal metastasis of non-small cell lung cancer].
  • To evaluate the optimum treatment strategy for metastatic adrenal tumors derived from non-small cell lung cancer (NSCLC), we retrospectively analyzed 17 consecutive cases (8 resection cases: 4 synchronous and 4 metachronous: 9 non-resection cases: 3 synchronous and 6 metachronous) who received surgical resection for NSCLC.
  • Of these, 9, 3, 2, 2, and 1 patient (s) were diagnosed as having adenocarcinoma, squamous cell carcinoma, pleomorphic carcinoma, large cell carcinoma, and adenosquamous cell carcinoma, respectively.
  • The mean interval after lung resection and treatment of metachronous adrenal metastasis was 9.9 months.
  • The mean time to progression from treatment of metachronous adrenal metastasis to disease progression was 8.9 months.
  • The 2-year survival of patients following resection versus those who did not undergo a resection for adrenal metastasis was 62.5 and 22.8%, respectively.
  • These data indicate that metastatic adrenal tumors should be resected if the patient can tolerate surgery after appropriate selection.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


30. Kosmidis C, Efthimiadis C, Anthimidis G, Levva S, Ioannidou G, Zaramboukas T, Emmanouilides C, Baka S, Kosmidou M, Basdanis G, Fachantidis E: Adrenalectomy for solitary adrenal metastasis from colorectal cancer: A case report. Cases J; 2008;1(1):49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenalectomy for solitary adrenal metastasis from colorectal cancer: A case report.
  • BACKGROUND: Patients with adrenal metastasis from various primary tumours are regarded as cases of diffuse systemic spread and considered unsuitable for surgical resection.
  • We herein report an operable case of heterochronic adrenal metastasis from colorectal carcinoma in a 63-year-old woman.
  • Four months later a right adrenal metastasis was detected by magnetic resonance imaging (MRI), as sole evidence of metastatic disease.
  • The histopathological examination revealed adenocarcinoma compatible with the colorectal carcinoma resected 19 months earlier.
  • The patient received adjuvant chemotherapy after each operation and is alive and free of disease 21 months after the adrenalectomy.
  • CONCLUSION: The possibility of adrenal metastasis should be considered in the follow-up of patients after primary surgery for colorectal cancer, even though other sites are the main metastatic sites.
  • Although the prognosis of adrenal metastasis from colorectal cancer is poor, we suggest that patients with solitary adrenal metastasis may benefit from complete removal of it.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Clin Oncol. 2000 Sep;30(9):414-6 [11095141.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1679-80 [12473894.001]
  • [Cites] Clin Nucl Med. 2003 Mar;28(3):238 [12592139.001]
  • [Cites] Surg Today. 2003;33(2):126-30 [12616376.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):103-5 [15011840.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):389-94 [9445197.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Oct;31(11):1699-701 [15553687.001]
  • [Cites] Hormones (Athens). 2006 Jan-Mar;5(1):52-6 [16728385.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):291-3 [17098665.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):1-13 [17786445.001]
  • [Cites] J Gastroenterol. 2004 Jun;39(6):594-5 [15235882.001]
  • (PMID = 18638404.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2503966
  •  go-up   go-down


31. Bandier PC, Hansen A, Thorelius L: [Adenomatoid tumour of the adrenal gland]. Ugeskr Laeger; 2009 Jan 26;171(5):306-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenomatoid tumour of the adrenal gland].
  • An adenomatoid tumour in the right suprarenal gland was discovered during clinical cancer staging of a 73-year-old woman.
  • A definitive diagnosis is made on the basis of histology since imaging methods are non-specific.
  • Differential diagnoses comprise malignant vascular neoplasm or adenocarcinoma.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ugeskr Laeger. 2009 Mar 16;171(12):1015; author reply 1015 [19306484.001]
  • (PMID = 19176156.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


32. Fiszer-Maliszewska L, Kazanowska B, Padzik J, Regional Blood Transfusion Center: p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma. Fam Cancer; 2009;8(4):541-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.
  • Germline p53 mutations are associated with Li-Fraumeni syndrome (LFS) and other familial cancer phenotypes not fulfilling the definition for LFS.
  • The germline mutation, R342X (16915C>T), and the novel mutation, R342P (16916G>C), were found in a child with adrenocortical carcinoma and in a LFS pediatric patient with multiple primaries.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Li-Fraumeni Syndrome / genetics. Protein Structure, Tertiary / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8424-9 [12826609.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2000;48(4):309-15 [11059649.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] J Natl Cancer Inst. 1992 May 6;84(9):703-7 [1569604.001]
  • [Cites] Oncogene. 2001 May 10;20(21):2611-7 [11420672.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):313-20 [12619118.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12324-9 [17620598.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):166-70 [8980144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] Fam Cancer. 2005;4(2):177-81 [15951970.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Oncogene. 1998 Jan 15;16(2):283-92 [9464547.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1298-304 [8118819.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):27-30 [15719270.001]
  • [Cites] Br J Cancer. 2001 Jan 5;84(1):116-9 [11139324.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3789-95 [17606709.001]
  • [Cites] Nat Struct Biol. 2002 Jan;9(1):12-6 [11753428.001]
  • [Cites] J Med Genet. 2008 Aug;45(8):535-8 [18511570.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1932-7 [10864200.001]
  • [Cites] Cancer Gene Ther. 2009 Jan;16(1):1-12 [18802452.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Feb;10(2):83-7 [11219776.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):372-6 [9766574.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):747-9 [2259385.001]
  • [Cites] Hum Mutat. 2000 Dec;16(6):482-90 [11102977.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5358-62 [3409256.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • (PMID = 19714490.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


33. Bitik B, Kalpakci Y, Altan E, Dogan E, Altundag K: Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen. Ann Oncol; 2009 Feb;20(2):394-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211504.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Jacobs B, Müller MK, Pfeiffer AF: [Diabetes mellitus and massive lower leg edema without heart failure]. Dtsch Med Wochenschr; 2005 Apr 29;130(17):1074-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypokalemia which was refractory to treatment raised the differential diagnosis of Conn's syndrome or ectopic secretion of ACTH, although these conditions are frequently associated with arterial hypertension.
  • Underlying reason was an adenocarcinoma of the pancreas with ectopic secretion of ACTH.
  • A treatment attempt with subcutaneous somatostatin and the adrenal enzyme inhibitor ketoconazole failed to control increased cortisol secretion.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Cholestasis / complications. Cholestasis / diagnosis. Cholestasis / etiology. Diagnosis, Differential. Heart Failure / complications. Heart Failure / diagnosis. Humans. Hydrocortisone / metabolism. Hypokalemia / complications. Hypokalemia / diagnosis. Male. Middle Aged. Pancreatic Neoplasms / complications. Pancreatic Neoplasms / diagnosis


35. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F, German and Austrian Adrenal Network: Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab; 2005 Jul;90(7):3886-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
  • Moreover, recent evidence has suggested that TZDs might have favorable effects in the treatment of a variety of tumors as differentiation-inducing agents.
  • Adrenocortical carcinoma (ACC) is a rare tumor entity with poor prognosis due to its highly malignant phenotype and lack of effective treatment options.
  • OBJECTIVE: The purpose of this study was to investigate effects of TZDs on adrenocortical cancer cells.
  • RESULTS: PPARgamma mRNA expression was detectable in all adrenocortical tumors including ACCs at similar levels.
  • Furthermore, incubation of the adrenocortical tumor cell line NCI h295 with the PPARgamma agonist rosiglitazone led to a decrease in cell viability, a decrease of cellular proliferation, and an increase in apoptosis as well as steroidogenesis.
  • On the molecular level, NCI h295 cells expressed higher levels of ACTH receptor (melanocortin receptor-2) mRNA upon treatment, whereas cyclin E mRNA was reduced, thus reflecting a shift toward an expression pattern found in less aggressive adrenocortical tumors in vivo.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. PPAR gamma / agonists. Thiazolidinediones / pharmacology
  • [MeSH-minor] Adult. Aged. Anilides / pharmacology. Apoptosis / drug effects. Cell Differentiation. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin E / genetics. Dose-Response Relationship, Drug. Female. Humans. Insulin-Like Growth Factor II / genetics. Male. Middle Aged. Promoter Regions, Genetic. RNA, Messenger / analysis. Receptor, Melanocortin, Type 2 / genetics

  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886257.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-chloro-5-nitrobenzanilide; 0 / Anilides; 0 / Cyclin E; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Receptor, Melanocortin, Type 2; 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


36. Cassoni P, Daniele L, Maldi E, Righi L, Tavaglione V, Novello S, Volante M, Scagliotti GV, Papotti M: Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases. Histopathology; 2009 Jul;55(1):20-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression in lung carcinoma varies according to tumour histotype and is acquired de novo in brain metastases.
  • AIMS: To study caveolin-1 (Cav-1) expression in metastatic lung carcinomas.
  • METHODS AND RESULTS: Cav-1 expression was investigated in a series of 121 lung carcinomas and it was shown that 18/121 tumours (14.9%) were Cav-1+.
  • None of the pure bronchioloalveolar carcinomas proved to be positive, vs. 42.8% of the large cell carcinomas (neuroendocrine subtype excluded).
  • Adenocarcinomas (8.5%), large cell neuroendocrine carcinomas (20%) and squamous cell carcinomas (29.6%) displayed an intermediate percentage of positive cases, suggesting a gradient of Cav-1 expression according to tumour histotype-related aggressiveness.
  • In 34 tumours metastatic to the brain, primary and secondary lesions were compared and 53% of brain metastases were Cav-1+ vs. 20.6% of primaries, indicating a de novo acquisition of Cav-1 expression.
  • This pattern was exclusive to the brain, as it was not acquired in adrenal metastases.
  • CONCLUSIONS: Cav-1 immunoreactivity in lung carcinoma is histotype-dependent and acquired de novo in brain metastases, suggesting a site-specific phenotypic shift in secondary lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Carcinoma, Large Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Caveolin 1 / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / secondary. DNA, Neoplasm / genetics. Disease Progression. Gene Amplification / genetics. Gene Expression Regulation, Neoplastic. Humans. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614763.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / DNA, Neoplasm; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


37. Cerquetti L, Sampaoli C, Amendola D, Bucci B, Misiti S, Raza G, De Paula U, Marchese R, Brunetti E, Toscano V, Stigliano A: Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. Int J Oncol; 2010 Aug;37(2):493-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
  • It also has a cytotoxic effect on the adrenocortical cells and represents a primary drug used in the adrenocortical carcinoma (ACC).
  • H295R and SW13 cell lines were treated with mitotane 10(-5) M and ionizing radiations (IR) in combination therapy, inducing an irreversible inhibition of cell growth in both adrenocortical cancer cells.
  • As shown in a previous report, mitotane/IR combination treatment induced a cell accumulation in the G2 phase.
  • Here, we report the radiosensitizing properties of mitotane in two different ACC cell lines.
  • Indeed, treatment with purvalanol, a cdc2-inhibitor prevents cell cycle arrest, triggering the G2/M transition.
  • The observation that mitotane and IR in combination treatment amplifies the activation level of cyclin B/cdc2 complexes contributing to cell cycle arrest, suggests that the MPF could function as a master signal for controlling the temporal order of different mitotic events.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiotherapy. Adrenocortical Carcinoma / radiotherapy. Cyclin B / metabolism. Cyclin-Dependent Kinases / metabolism. DNA Repair Enzymes / metabolism. Mitotane / pharmacology
  • [MeSH-minor] Cell Proliferation / drug effects. Cell Proliferation / radiation effects. DNA Mismatch Repair / drug effects. DNA Mismatch Repair / physiology. Drug Evaluation, Preclinical. G2 Phase / drug effects. G2 Phase / physiology. Humans. Multiprotein Complexes / metabolism. Protein Kinase Inhibitors / pharmacology. Purines / pharmacology. Radiation, Ionizing. Radiation-Sensitizing Agents / pharmacology. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. MITOTANE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596677.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine; 0 / Cyclin B; 0 / Multiprotein Complexes; 0 / Protein Kinase Inhibitors; 0 / Purines; 0 / Radiation-Sensitizing Agents; 78E4J5IB5J / Mitotane; EC 2.7.11.22 / Cyclin-Dependent Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


38. Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao C, Morange I, Picó A, Ouzounian S, Young J, Hahner S, Brue T, Allolio B, Conte-Devolx B: Merits and pitfalls of mifepristone in Cushing's syndrome. Eur J Endocrinol; 2009 Jun;160(6):1003-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty patients with malignant (n=15, 12 with adrenocortical carcinoma, three with ectopic ACTH secretion) or benign (n=5, four with Cushing's disease, one with bilateral adrenal hyperplasia) CS were treated with mifepristone.
  • Median treatment duration was 2 months (0.25-21) for malignant CS, and 6 months (0.5-24) for benign CS.
  • Clinical (signs of hypercortisolism, blood pressure, signs of adrenal insufficiency), and biochemical parameters (serum potassium and glucose) were evaluated.
  • Improvement of clinical signs was observed in 11/15 patients with malignant CS (73%), and 4/5 patients with benign CS (80%).
  • Signs of adrenal insufficiency were observed in 3/20 patients.
  • CONCLUSION: Mifepristone is a rapidly effective treatment of hypercortisolism, but requires close monitoring of potentially severe hypokalemia, hypertension, and clinical signs of adrenal insufficiency.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • The Lens. Cited by Patents in .
  • University of Turin Instituional Repository AperTO. Full Text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289534.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


39. Hu X, Dietz JD, Xia C, Knight DR, Loging WT, Smith AH, Yuan H, Perry DA, Keiser J: Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition. Endocrinology; 2009 May;150(5):2211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The direct effects of torcetrapib and related molecules on adrenal steroid production were assessed in cell culture using the H295R as well as the newly developed HAC15 human adrenal carcinoma cell lines.
  • Torcetrapib induced the synthesis of both aldosterone and cortisol in these two in vitro cell systems.
  • Transcription profiling indicated that torcetrapib and angiotensin II share overlapping pathways in regulating adrenal steroid biosynthesis.
  • Consistent with intracellular calcium being the key mediator of torcetrapib's effect in adrenal cells, calcium channel blockers completely blocked torcetrapib-induced corticoid release and calcium increase.
  • The results indicate that the pressor and adrenal effects observed with torcetrapib and related molecules are independent of CETP inhibition.
  • [MeSH-minor] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. Anticholesteremic Agents / adverse effects. Anticholesteremic Agents / chemistry. Anticholesteremic Agents / pharmacology. Blood Pressure / drug effects. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cytochrome P-450 CYP11B2 / genetics. Cytochrome P-450 CYP11B2 / metabolism. Drug Evaluation, Preclinical. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Fluid / drug effects. Intracellular Fluid / metabolism. Models, Biological. Steroid 11-beta-Hydroxylase / genetics. Steroid 11-beta-Hydroxylase / metabolism. Structure-Activity Relationship


40. Hofland J, Timmerman MA, de Herder WW, van Schaik RH, de Krijger RR, de Jong FH: Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Clin Endocrinol (Oxf); 2006 Dec;65(6):792-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
  • OBJECTIVE: The growth and differentiation factors activin and inhibin can affect tumour formation and steroid production in the adrenal cortex.
  • Expression of these activin-related mRNAs was measured in different types of adrenocortical tissues and tumours to study the relationship with tumorigenesis.
  • DESIGN: Quantitative expression of activin-related mRNAs was investigated in patient adrenocortical samples.
  • PATIENTS: Twenty-eight human adrenocortical samples from normal and hyperplastic adrenals and from adrenocortical adenomas and carcinomas were collected after surgery for study purposes.
  • MEASUREMENTS: Using quantitative reverse transcription polymerase chain reaction (RT-PCR), we investigated the expression of inhibin alpha-, betaA- and betaB-subunits, follistatin, betaglycan, ActRIIA, ActRIIB and Alk-4 in the adrenocortical tissues.
  • RESULTS: All genes studied were expressed in all tissues, with the exception of the inhibin alpha-subunit in one hyperplastic adrenal and three adrenocortical carcinomas.
  • Expression of inhibin betaA-subunit, follistatin, betaglycan, ActRIIA, ActRIIB and CYP17 differed between nontumorous adrenals and carcinomas.
  • We conclude that the expression of activin and inhibin subunits, receptors and binding proteins is affected by tumour formation in the adrenal gland and may play a role in tumorigenesis.
  • [MeSH-major] Activins / metabolism. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Inhibins / metabolism
  • [MeSH-minor] Activin Receptors, Type II / genetics. Activin Receptors, Type II / metabolism. Adrenal Cortex / metabolism. Adrenal Cortex / pathology. Adult. Carrier Proteins / genetics. Carrier Proteins / metabolism. Female. Follistatin / genetics. Follistatin / metabolism. Gene Expression. Humans. Hyperplasia. Inhibin-beta Subunits / genetics. Inhibin-beta Subunits / metabolism. Male. Middle Aged. Proteoglycans / genetics. Proteoglycans / metabolism. Receptors, Transforming Growth Factor beta / genetics. Receptors, Transforming Growth Factor beta / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Steroid 17-alpha-Hydroxylase / genetics. Steroid 17-alpha-Hydroxylase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121532.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Follistatin; 0 / Proteoglycans; 0 / Receptors, Transforming Growth Factor beta; 0 / inhibin beta A subunit; 0 / inhibin-alpha subunit; 104625-48-1 / Activins; 145170-29-2 / betaglycan; 57285-09-3 / Inhibins; 93443-12-0 / Inhibin-beta Subunits; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


41. Raunio H, Hakkola J, Pelkonen O: Regulation of CYP3A genes in the human respiratory tract. Chem Biol Interact; 2005 Jan 15;151(2):53-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CYP3A5 protein is present in the liver and some extrahepatic tissues, such as the gut wall, kidney, adrenal gland, prostate and many cell types in the lung.
  • CYP3A5 is upregulated by glucocorticoids via the glucocorticoid receptor (GR) in lung adenocarcinoma derived A549 cells.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698577.001).
  • [ISSN] 0009-2797
  • [Journal-full-title] Chemico-biological interactions
  • [ISO-abbreviation] Chem. Biol. Interact.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / CYP3A protein, human; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  • [Number-of-references] 55
  •  go-up   go-down


42. Brau-Javier CN, Sánchez JL: Cutaneous adrenal cortical carcinoma metastasis in a 6 year-old boy. P R Health Sci J; 2010 Sep;29(3):330-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous adrenal cortical carcinoma metastasis in a 6 year-old boy.
  • We report the case of a six year-old boy with a history of adrenal cortical carcinoma presenting with cutaneous metastasis.
  • Due to the low incidence of cutaneous metastasis arising from adrenal cortical carcinoma, its diagnosis can be challenging based solely on histological analysis.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / secondary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20799523.001).
  • [ISSN] 0738-0658
  • [Journal-full-title] Puerto Rico health sciences journal
  • [ISO-abbreviation] P R Health Sci J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


43. Kvacheniuk AN: [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection]. Klin Khir; 2008 Mar;(3):34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of adrenocortical cancer: significance of systematic lymphodissection].
  • Comparative efficacy of radical methods of surgical intervention for adrenocortical cancer (ACC) with lymphodissection (LD) and without it was studied.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680995.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


44. Padberg BC, Rordorf T, Suter SL, Pfeiffer D, Wild D, Schröder S: [123I-Metaiodobenzylguanidine- (MIBG-) scintigraphy: paradoxical positivity in an oncocytic adrenocortical carcinoma]. Pathologe; 2007 Jul;28(4):281-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [123I-Metaiodobenzylguanidine- (MIBG-) scintigraphy: paradoxical positivity in an oncocytic adrenocortical carcinoma].
  • In contrast, the false-positive uptake of MIBG by adrenal cortical carcinoma is rare.
  • Here, we report a metastatic oncocytic adrenal cortical carcinoma with MIBG uptake used for therapeutic purposes.
  • [MeSH-major] 3-Iodobenzylguanidine. Adrenal Cortex Neoplasms / diagnostic imaging. Iodine Radioisotopes
  • [MeSH-minor] Adrenal Gland Neoplasms / diagnostic imaging. Diagnosis, Differential. Humans. Neoplasm Metastasis. Pheochromocytoma / diagnostic imaging. Pheochromocytoma / pathology. Radioisotopes. Radionuclide Imaging

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Q J Nucl Med. 1995 Dec;39(4 Suppl 1):13-6 [9002742.001]
  • [Cites] Clin Nucl Med. 1990 Nov;15(11):821-4 [2292157.001]
  • [Cites] Lab Invest. 1995 Apr;72(4):424-31 [7723281.001]
  • [Cites] J Nucl Med. 1985 Jun;26(6):576-85 [2860214.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):89-96 [2114700.001]
  • [Cites] J Endocrinol Invest. 1998 Dec;21(11):779-83 [9972680.001]
  • [Cites] Clin Nucl Med. 1994 Mar;19(3):221-3 [8033473.001]
  • [Cites] Nucl Med Commun. 2002 Oct;23 (10 ):951-60 [12352593.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2003 Apr;111(2):111-4 [12746763.001]
  • [Cites] Br J Clin Pract. 1990 Oct;44(10 ):411-2 [2268520.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Clin Nucl Med. 1988 Oct;13(10 ):730-3 [2902945.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;420(1):65-70 [1539453.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2003 Aug;111(5):294-7 [12951637.001]
  • [Cites] Clin Nucl Med. 2002 Jul;27(7):479-82 [12072772.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):549-56 [1755111.001]
  • [Cites] Lab Invest. 1992 Feb;66(2):169-74 [1735954.001]
  • [Cites] Clin Nucl Med. 1991 Apr;16(4):239-42 [2044316.001]
  • [Cites] Horm Res. 1996;46(3):138-42 [8894669.001]
  • (PMID = 16673076.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


45. Brauckhoff M, Dralle H: [Recurrent operations on the adrenal glands]. Chirurg; 2005 Mar;76(3):227-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent operations on the adrenal glands].
  • Repeat adrenalectomy may be required due to ipsilateral recurrence of benign or malignant adrenal tumors after previous total or subtotal adrenalectomy.
  • Even for multivisceral resection in patients with adrenocortical carcinoma, complete resection of local recurrent tumor offers results similar to those of primary resection (5-year survival 40-60%).
  • In any case, during open or endoscopic approach, tumor spillage must be avoided to prevent local tumor cell implantation.
  • Following subtotal adrenalectomy, the risk of ipsilateral recurrence correlates with disease, follow-up, localization, size of the adrenal remnant, and, in case of familial pheochromocytoma, probably with genotype.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Pheochromocytoma / surgery
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Male. Middle Aged. Mitotane / therapeutic use. Octreotide / therapeutic use. Palliative Care. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / surgery. Radiotherapy, Adjuvant. Reoperation

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Endourol. 1999 Mar;13(2):99-104; discussion 104-6 [10213103.001]
  • [Cites] Arch Surg. 2001 May;136(5):543-9 [11343545.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] Ann Thorac Surg. 1996 Jan;61(1):222-4 [8561564.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Eur J Surg. 1999 May;165(5):431-5 [10391158.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):325-9 [1973322.001]
  • [Cites] World J Surg. 2000 Nov;24(11):1347-52 [11038205.001]
  • [Cites] World J Surg. 2004 Dec;28(12):1323-9 [15517476.001]
  • [Cites] World J Surg. 2000 Jan;24(1):108-13 [10594213.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Eur J Endocrinol. 2004 Jun;150(6):789-92 [15191348.001]
  • [Cites] Surgery. 2003 Dec;134(6):1020-7; discussion 1027-8 [14668736.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1005-12 [12045858.001]
  • [Cites] World J Surg. 1998 Jun;22(6):621-6; discussion 626-7 [9597938.001]
  • [Cites] N Engl J Med. 1977 Jun 2;296(22):1269-71 [859517.001]
  • [Cites] Endocr J. 2002 Apr;49(2):227-9 [12081243.001]
  • [Cites] Surgery. 1995 Dec;118(6):1090-8 [7491528.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Horm Res. 2002;57(5-6):197-9 [12053093.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surg Today. 2004;34(3):251-5 [14999539.001]
  • [Cites] Surgery. 1985 Jan;97(1):16-20 [3966225.001]
  • [Cites] Surgery. 2000 Dec;128(6):1007-11;discussion 1011-2 [11114636.001]
  • [Cites] Endocr Rev. 2001 Feb;22(1):75-110 [11159817.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):719-26 [10622498.001]
  • [Cites] Chirurg. 2003 May;74(5):473-7 [12748796.001]
  • [Cites] World J Surg. 1990 May-Jun;14(3):330-4 [2368435.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jan;85(1):5-7 [10634355.001]
  • [Cites] J Am Coll Surg. 2004 Apr;198(4):525-34; discussion 534-5 [15051000.001]
  • [Cites] J Pediatr Surg. 1993 Oct;28(10):1248-51; discussion 1251-2 [8263682.001]
  • [Cites] J Intern Med. 1995 Oct;238(4):363-7 [7595173.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Nov;69(5):1078-81 [2793991.001]
  • [Cites] Eur J Surg. 1999 Jun;165(6):535-8 [10433135.001]
  • [Cites] Surgery. 2003 Dec;134(6):956-62; discussion 962-3 [14668728.001]
  • [Cites] Surgery. 1996 Dec;120(6):1064-70; discussion 1070-1 [8957496.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Jan;46(1):39-44 [9059556.001]
  • [Cites] World J Surg. 1992 Jul-Aug;16(4):753-8 [1413845.001]
  • [Cites] Surgery. 2002 Dec;132(6):1008-11; discussion 1012 [12490848.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2004 Aug;14(4):234-5 [15345163.001]
  • [Cites] J Urol. 1997 Jun;157(6):2239 [9146626.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] J Urol. 1999 Feb;161(2):395-8 [9915410.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4083-7 [12970267.001]
  • [Cites] J Urol. 2000 Jul;164(1):14-7 [10840414.001]
  • [Cites] Arch Surg. 2002 Jun;137(6):682-8; discussion 688-9 [12049539.001]
  • [Cites] World J Surg. 1982 Jul;6(4):397-402 [7123976.001]
  • [Cites] World J Surg. 1984 Aug;8(4):612-21 [6148811.001]
  • [Cites] Surgery. 1997 Dec;122(6):1068-73; discussion 1073-4 [9426421.001]
  • [Cites] ANZ J Surg. 2003 Aug;73(8):664-6 [12887546.001]
  • [Cites] Horm Res. 1999;52(2):97-100 [10681640.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):344-8 [10940711.001]
  • [Cites] Minn Med. 1974 Dec;57(12):951-2 [4424014.001]
  • [Cites] Eur J Endocrinol. 2004 Jul;151(1):15-27 [15248818.001]
  • [Cites] J Endourol. 2002 Apr;16(3):171-4 [12028627.001]
  • [Cites] Chirurg. 1989 Apr;60(4):266-71; discussion 271-2 [2566455.001]
  • [Cites] Arch Surg. 1974 Apr;108(4):450-4 [4815920.001]
  • [Cites] Front Horm Res. 2004;31:155-62 [14674310.001]
  • [Cites] Surgery. 1997 Dec;122(6):1212-8 [9426440.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):94-7 [10027369.001]
  • [Cites] J Urol. 1998 Aug;160(2):330-4 [9679871.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] Surgery. 1983 Dec;94(6):938-40 [6648808.001]
  • [Cites] Henry Ford Hosp Med J. 1987;35(2-3):127-8 [2891644.001]
  • (PMID = 15739057.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 35MRW7B4AD / 3-Iodobenzylguanidine; 78E4J5IB5J / Mitotane; RWM8CCW8GP / Octreotide
  • [Number-of-references] 45
  •  go-up   go-down


46. Sane T: [Mitotane in the treatment of adrenal carcinoma]. Duodecim; 2010;126(17):2040-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mitotane in the treatment of adrenal carcinoma].
  • Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma.
  • It reduces local recurrence of the disease and development of metastases even after a seemingly total surgical removal of the tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053521.001).
  • [ISSN] 0012-7183
  • [Journal-full-title] Duodecim; lääketieteellinen aikakauskirja
  • [ISO-abbreviation] Duodecim
  • [Language] fin
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Finland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


47. Wittekind C: [TNM 2010. What's new?]. Pathologe; 2010 Oct;31 Suppl 2:153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the seventh edition of the TNM Classification of Malignant Tumours there are several entirely new classifications: upper aerodigestive mucosal melanoma, gastrointestinal stromal tumour, gastrointestinal carcinoid (neuroendocrine tumour), intrahepatic cholangiocarcinoma, Merkel cell carcinoma, uterine sarcomas, and adrenal cortical carcinoma.
  • Significant modifications concern carcinomas of the oesophagus, oesophagogastric junction, stomach, appendix, biliary tract, lung, skin, prostate and ophthalmic tumours, which will be not addressed in this article.
  • [MeSH-minor] Adrenal Cortex Neoplasms / classification. Adrenal Cortex Neoplasms / pathology. Bile Duct Neoplasms / classification. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Carcinoid Tumor / classification. Carcinoid Tumor / pathology. Carcinoma, Merkel Cell / classification. Carcinoma, Merkel Cell / pathology. Cholangiocarcinoma / classification. Cholangiocarcinoma / pathology. Digestive System Neoplasms / classification. Digestive System Neoplasms / pathology. Female. Gastrointestinal Stromal Tumors / classification. Gastrointestinal Stromal Tumors / pathology. Humans. Respiratory Tract Neoplasms / classification. Respiratory Tract Neoplasms / pathology. Sarcoma / classification. Sarcoma / pathology. Skin Neoplasms / classification. Skin Neoplasms / pathology. Uterine Neoplasms / classification. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Ann Surg. 2010 Jan;251(1):46-50 [20032718.001]
  • [Cites] Cancer. 2010 Aug 15;116(16):3763-73 [20564099.001]
  • [Cites] Virchows Arch. 2010 Jun;456(6):595-7 [20422210.001]
  • [Cites] Dis Esophagus. 2009;22(1):1-8 [19196264.001]
  • [Cites] Biostatistics. 2009 Oct;10(4):603-20 [19502615.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] Pathologe. 2010 Sep;31(5):374-8 [20703482.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):757-62 [17674042.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Nov;95(11):4925-32 [20668036.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):647-9 [15612025.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2507-16 [15856474.001]
  • (PMID = 20737151.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Mohammad K, Sadikot RT: Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. South Med J; 2009 Jun;102(6):665-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer.
  • The adrenals are a common site of metastases for lung cancers; adrenal insufficiency, however, as a presenting feature of lung cancer, is extremely rare.
  • We report a case of primary adrenal insufficiency secondary to metastases from adenocarcinoma of the lung.
  • CT scans showed a right upper lobe mass and bilateral adrenal masses.
  • The frequent occurrence of constitutional symptoms, metabolic derangements, and cardiovascular compromise in patients with advanced cancer may lead to an underestimation of the true incidence of adrenal insufficiency in this population.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Insufficiency / etiology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology


49. Benavente-Chenhalls LA, Vella A, Farley DR, Thompson GB, Grant CS, Richards ML: Malignant adrenal neoplasm masquerading as worrisome adrenal hemorrhage. Ann Surg Oncol; 2010 Oct;17(10):2710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant adrenal neoplasm masquerading as worrisome adrenal hemorrhage.
  • BACKGROUND: Adrenal hemorrhage (AH) associated with adrenal neoplasm is rare.
  • This study assesses the clinical and pathological impact of AH in the setting of malignant adrenal neoplasm to establish management strategies.
  • MATERIALS AND METHODS: Patients admitted over a 25-year period with a diagnosis of AH and malignant adrenal neoplasm were retrospectively reviewed.
  • RESULTS: Malignant adrenal neoplasms were reported in 14 of 217 patients (6.4%) presenting with AH.
  • In 10 patients the adrenal tumor was metastatic.
  • Four patients had adrenocortical carcinoma (ACC).
  • All primary adrenal tumors were unilateral.
  • Computed tomography (n = 12) demonstrated adrenal masses ranging in size from 6.8 to 11.0 cm (mean, 9 cm).
  • CONCLUSION: Most patients with AH in the setting of malignant adrenal neoplasm had metastatic tumors to the adrenal glands.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Adrenal Gland Neoplasms / diagnosis. Hemorrhage / complications. Hemorrhage / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20499282.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Parnaby CN, Galbraith N, O'Dwyer PJ: Experience in identifying the venous drainage of the adrenal gland during laparoscopic adrenalectomy. Clin Anat; 2008 Oct;21(7):660-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience in identifying the venous drainage of the adrenal gland during laparoscopic adrenalectomy.
  • Laparoscopic adrenalectomy (LA) is the procedure of choice for most adrenal tumors.
  • An important part of LA is the early identification and ligation of the adrenal veins.
  • The venous drainage from each adrenal gland is usually via a single vein: the right vein draining into the inferior vena cava (IVC) and the left vein into the left renal vein.
  • The aim of the study was to clarify if LA identified venous drainage and its variants.
  • Between January 1999 and January 2008, 142 consecutive patients underwent LA.
  • Adrenal vein anatomy was documented on a prospective database.
  • In total, 142 patients underwent 162 LA (right = 62, left = 66, bilateral = 17).
  • All adrenal veins were identified at the time of laparoscopy.
  • For 157 LA, the adrenal venous drainage was constant: right vein drained into the IVC and left vein drained into left renal vein.
  • Five patients had adrenal vein variants: two right veins draining separately into IVC (n = 1), two right veins draining into the IVC and right renal vein (n = 1), and two left veins draining separately into the left renal vein (n = 3).
  • Adrenal vein variants were present in patients with phaeochromocytomas (n = 4) or adrenocortical carcinoma (n = 1).
  • The laparoscopic approach allowed an excellent view of the main adrenal venous anatomy.
  • This has helped confirm the constant nature of the venous drainage and successfully identify variant adrenal veins.
  • [MeSH-major] Adrenal Glands / blood supply. Adrenalectomy. Laparoscopy. Veins / anatomy & histology
  • [MeSH-minor] Adrenal Cortex Neoplasms / surgery. Adrenal Gland Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Pheochromocytoma / surgery. Renal Veins / anatomy & histology. Vena Cava, Inferior / anatomy & histology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18816449.001).
  • [ISSN] 1098-2353
  • [Journal-full-title] Clinical anatomy (New York, N.Y.)
  • [ISO-abbreviation] Clin Anat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Sugawara T, Nomura E, Hoshi N: Cholesterol sulphate affects production of steroid hormones by reducing steroidogenic acute regulatory protein level in adrenocortical cells. J Endocrinol; 2007 Dec;195(3):451-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cholesterol sulphate affects production of steroid hormones by reducing steroidogenic acute regulatory protein level in adrenocortical cells.
  • Cholesterol sulphate (CS), which is present ubiquitously in mammalian tissues, is not only a precursor of sulphated adrenal steroids but also an inhibitor of cholesterol biosynthesis.
  • This study was designed to examine the biological roles of CS in steroidogenesis in adrenocortical cells.
  • Human adrenocortical carcinoma H295R cells were cultured with various amounts of CS.
  • Western blot analysis was performed to determine StAR protein level using whole cell extracts from cells.
  • In conclusion, CS affects the production of steroid hormones by reducing StAR protein level in adrenocortical cells.
  • [MeSH-major] Adrenal Cortex / cytology. Adrenal Cortex / metabolism. Cholesterol Esters / metabolism. Hormones / biosynthesis. Phosphoproteins / antagonists & inhibitors. Steroids / biosynthesis
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Culture Media / chemistry. Gene Expression / drug effects. Genes, Reporter. Humans. Pregnenolone / analysis. Pregnenolone / biosynthesis. Promoter Regions, Genetic. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection

  • MedlinePlus Health Information. consumer health - Hormones.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18000307.001).
  • [ISSN] 1479-6805
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cholesterol Esters; 0 / Culture Media; 0 / Hormones; 0 / Phosphoproteins; 0 / RNA, Messenger; 0 / Steroids; 0 / steroidogenic acute regulatory protein; 73R90F7MQ8 / Pregnenolone; KU576NT9O9 / cholesteryl sulfate
  •  go-up   go-down


52. Gockel I, Heintz A, Domeyer M, Trinh TT, Dünschede F, Junginger T: [Indications for conventional adrenalectomy]. Zentralbl Chir; 2008 Jun;133(3):255-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Indications for conventional adrenalectomy were - as compared with the minimally invasive procedure - significantly more frequent adrenocortical carcinomas (ACC), especially in the context of multivisceral resections, as well as adrenal metastases (synchronous and metachronous).
  • In contrast, adrenal Cushing's disease (including 19 patients with bilateral tumours), pheochromocytoma, incidentaloma and Conn's syndrome constituted a more frequent indication for minimally invasive adrenalectomy.
  • Conventionally operated adrenal pathologies with on average 6.0 (range: 1.2-19.0) cm diameter were significantly larger than the endoscopically removed tumours with on average 3.3 (range: 0.2-9.2) cm diameter (p < 0.0001).
  • The side localisation and the frequency of bilateral adrenal tumours did not differ significantly in the two groups.
  • CONCLUSION: Since the establishment of the minimally invasive technique in 1994, conventional adrenalectomy has been selected for 26 % of all resected adrenal pathologies at our clinic and, therefore, still plays an important role even in the era of laparoscopic surgery.
  • The benefit of the laparoscopic procedure in the case of malignant pheochromocytoma, adrenocortical carcinoma, and isolated adrenal metastases at a locally confined stage is still unclear and requires prospective, randomised studies.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Adrenalectomy / utilization. Minimally Invasive Surgical Procedures / utilization
  • [MeSH-minor] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenal Glands / pathology. Adult. Aged. Aged, 80 and over. Cushing Syndrome / pathology. Cushing Syndrome / surgery. Female. Humans. Hyperaldosteronism / pathology. Hyperaldosteronism / surgery. Male. Mathematical Computing. Middle Aged. Pheochromocytoma / pathology. Pheochromocytoma / surgery. Utilization Review / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18563692.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Gul W, Qazi AM, Barde C: Gastric carcinoma presenting with adrenal insufficiency caused by bilateral adrenal metastasis. Gastrointest Endosc; 2008 Nov;68(5):998; discussion 999
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric carcinoma presenting with adrenal insufficiency caused by bilateral adrenal metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Adrenal Insufficiency / etiology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18547572.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Li FY, Ren XB, Xu EP, Huang Q, Sheng HQ, Lv BJ, Lai MD: RegIV expression showing specificity to gastrointestinal tract and its potential role in diagnosing digestive tract neuroendocrine tumor. J Zhejiang Univ Sci B; 2010 Apr;11(4):258-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To learn more about RegIV, we evaluated its distribution by immunohistochemistry (IHC) in a total of 360 samples including 24 types of normal tissue, 40 benign and malignant lesions, and 18 neuroendocrine tumors.
  • We found that in normal tissues, in addition to its relative specificity for the gastrointestinal tract, RegIV was detected in the adrenal gland and mammary gland.
  • Studies on additional sets of colorectal tumor samples showed that RegIV expression was predominant in colorectal adenoma (87.5%) and peritumoral tissue (100%) but not in cancer tissue (30.8%).
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Gastrointestinal Tract / metabolism. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Lectins, C-Type / biosynthesis. Neuroendocrine Tumors / metabolism

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2000 Feb;13(2):140-6 [10697270.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):59-69 [19740514.001]
  • [Cites] Biochim Biophys Acta. 2001 Apr 16;1518(3):287-93 [11311942.001]
  • [Cites] Diabetes. 2002 Feb;51(2):339-46 [11812740.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):185-93 [12455032.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):11-20 [12819006.001]
  • [Cites] Cancer Lett. 2003 Oct 8;200(1):69-76 [14550954.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):963-9 [14559978.001]
  • [Cites] World J Gastroenterol. 2003 Dec;9(12):2635-41 [14669303.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1130-6 [15022278.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] J Am Coll Surg. 1994 Aug;179(2):231-48 [8044398.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2237-43 [15788672.001]
  • [Cites] J Pathol. 2005 Oct;207(2):185-98 [16086444.001]
  • [Cites] Gut. 2005 Oct;54(10):1437-44 [15914572.001]
  • [Cites] Gastroenterology. 2006 Jan;130(1):137-49 [16401477.001]
  • [Cites] Cancer Sci. 2006 Nov;97(11):1191-7 [16918991.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1714-20 [17106246.001]
  • [Cites] Lab Invest. 2007 Mar;87(3):304-14 [17260007.001]
  • [Cites] Oncology. 2007;72(5-6):371-80 [18187959.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [ErratumIn] J Zhejiang Univ Sci B. 2010 May;11(5):390
  • (PMID = 20349522.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / REG4 protein, human
  • [Other-IDs] NLM/ PMC2852542
  •  go-up   go-down


55. Waalkes MP, Liu J, Diwan BA: Transplacental arsenic carcinogenesis in mice. Toxicol Appl Pharmacol; 2007 Aug 1;222(3):271-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In C3H mice, two separate studies show male offspring exposed to arsenic in utero developed liver carcinoma and adrenal cortical adenoma in a dose-related fashion during adulthood.
  • Prenatally exposed female C3H offspring show dose-related increases in ovarian tumors and lung carcinoma and in proliferative lesions (tumors plus preneoplastic hyperplasia) of the uterus and oviduct.
  • Male CD1 mice treated with arsenic in utero develop tumors of the liver and adrenal and renal hyperplasia while females develop tumors of urogenital system, ovary, uterus and adrenal and hyperplasia of the oviduct.
  • Additional postnatal treatment with diethylstilbestrol or tamoxifen after prenatal arsenic in CD1 mice induces urinary bladder transitional cell proliferative lesions, including carcinoma and papilloma, and enhances the carcinogenic response in the liver of both sexes.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Carcinog. 1997 Aug;19(4):236-42 [9290700.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):209-18 [9219559.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Toxicol Sci. 1998 Aug;44(2):185-90 [9742656.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1489-97 [9788961.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1775-85 [9846968.001]
  • [Cites] Pediatr Nephrol. 1999 Feb;13(2):171-8 [10229008.001]
  • [Cites] Carcinogenesis. 1999 Sep;20(9):1873-6 [10469637.001]
  • [Cites] Exp Cell Res. 2005 Jan 1;302(1):96-107 [15541729.001]
  • [Cites] Chem Res Toxicol. 2004 Dec;17(12):1733-42 [15606151.001]
  • [Cites] Toxicol Sci. 2005 Feb;83(2):237-45 [15537745.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:269-477 [15645578.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):27-35 [15890234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8644-9 [15937110.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2179-86 [16014701.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8217-28 [16355251.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1337-45 [16452187.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Environ Health Perspect. 2006 Mar;114(3):404-11 [16507464.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Jun 15;213(3):216-23 [16368122.001]
  • [Cites] Toxicology. 2006 Jul 5;224(1-2):147-55 [16753250.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1293-6 [16882542.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Sep 15;215(3):295-305 [16712894.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Jul 1;166(1):24-35 [10873715.001]
  • [Cites] J Natl Cancer Inst Monogr. 2000;(27):135-45 [10963625.001]
  • [Cites] Toxicol Sci. 2001 Jan;59(1):68-74 [11134545.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5389-95 [11454681.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Oct 1;176(1):64-71 [11578149.001]
  • [Cites] Environ Health Perspect. 2002 Apr;110(4):331-6 [11940449.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1387-97 [12151359.001]
  • [Cites] Chem Res Toxicol. 2002 Sep;15(9):1150-7 [12230408.001]
  • [Cites] Environ Health Perspect. 2002 Oct;110 Suppl 5:767-71 [12426129.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Dec 15;193(3):309-34 [14678742.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):133-41 [14514661.001]
  • [Cites] Toxicol Sci. 2004 Feb;77(2):249-57 [14691202.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):466-74 [15026472.001]
  • [Cites] Environ Health Perspect. 2004 Apr;112(5):599-603 [15064167.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Aug 1;198(3):327-35 [15276412.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1779-86 [15073043.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):142-50 [15313586.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1975 Mar;35(3):766-80 [1167809.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Nov 17;376(2):117-32 [145710.001]
  • [Cites] Carcinogenesis. 1981;2(11):1087-94 [6797749.001]
  • [Cites] Teratology. 1987 Feb;35(1):19-25 [3563933.001]
  • [Cites] Toxicol Pathol. 1988;16(3):340-9 [3194656.001]
  • [Cites] Cancer Lett. 1993 Feb;68(2-3):193-8 [8443792.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3874-6 [8358711.001]
  • [Cites] Pathology. 1994 Apr;26(2):154-60 [7522317.001]
  • [Cites] Carcinogenesis. 1995 Aug;16(8):1993-6 [7634431.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Carcinogenesis. 1997 Oct;18(10):2009-14 [9364013.001]
  • (PMID = 17306315.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / Intramural NIH HHS / / Z01 BC005488-21; United States / Intramural NIH HHS / / Z99 ES999999; United States / NCI NIH HHS / CO / N01-CO-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Arsenicals; 0 / Carcinogens; 0 / Estrogens; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS28781; NLM/ PMC1995036
  •  go-up   go-down


56. Jani P, Nasr AL, Demellawy DE: Synchronous renal cell carcinoma and adrenocortical carcinoma: a rare case report and clinicopathologic approach. Can J Urol; 2008 Apr;15(2):4016-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous renal cell carcinoma and adrenocortical carcinoma: a rare case report and clinicopathologic approach.
  • A case of synchronous adrenocortical carcinoma (ACC) and renal cell carcinoma (RCC) has not yet been described in the English medical literature, to our knowledge.
  • We report a first such case of adrenocortical and renal cell carcinomas occurring simultaneously in a 53-year-old male.
  • Ultrasound followed by a computed tomography (CT) scan and a magnetic resonance imaging (MRI) examination revealed a 6.4 cm left adrenal mass and a 3.5 cm right renal mass.
  • Clinical and pathological clues that led to the diagnosis are discussed in detail.
  • [MeSH-major] Adrenocortical Carcinoma / epidemiology. Carcinoma, Renal Cell / epidemiology. Kidney Neoplasms / epidemiology. Neoplasms, Multiple Primary / epidemiology


57. Pusantisampan T, Sangkhathat S, Kayasut K, Kanngurn S, Jaruratanasirikul S, Chotsampancharoen T, Kritsaneepaiboon S: Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin. Pediatr Dev Pathol; 2010 May-Jun;13(3):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.
  • A role of beta-catenin (CTNNB1) in the molecular pathogenesis of adrenocortical carcinoma (ACC) has been suspected in adult ACC and pediatric pigmented nodular adrenocortical disease, but it has never been reported in pediatric ACC.
  • We present the case of a 4-month-old Thai infant who had Cushing's syndrome secondary to bilateral adrenal tumors with hepatic metastasis.
  • Histopathology revealed bilateral adrenocortical tumors with different histologic grades; the right tumor had a higher score, according to modified Weiss criteria.
  • On molecular study, a deletion mutation of beta-catenin involving codons 44 to 45 was detected in the right adrenal tumor.
  • Immunohistochemistry showed nuclear accumulation of beta-catenin on the right adrenal tumor and the metastatic nodule.
  • In summary, we present evidence that supports the role of the Wnt-signaling pathway in the carcinogenesis of pediatric adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / complications. Adrenocortical Carcinoma / complications. Cushing Syndrome / etiology. Gene Deletion. Liver Neoplasms / complications. beta Catenin / genetics

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863445.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


58. Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A: Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):233-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of adrenal incidentaloma.
  • Clinically inapparent adrenal masses, or adrenal incidentalomas, are discovered inadvertently in the course of work-up or treatment of unrelated disorders.
  • Cortical adenoma is the most frequent tumour detected incidentally, but adrenocortical cancer, phaeochromocytoma and metastasis are not rare.
  • Two critical questions should be answered before trying to outline the management of adrenal incidentaloma:.
  • (1) identify either primary (adrenocortical cancer) or secondary (adrenal metastasis) malignancy;.
  • Radiological evaluation is the key to the differential diagnosis of benign and malignant tumours.
  • Endocrine testing is necessary to exclude phaeochromocytoma in all patients with an adrenal incidentaloma because this tumour may remain undiagnosed after imaging studies.
  • The management of clinically inapparent adrenal adenomas may vary depending whether or not they are functioning.
  • Also the management of this condition is largely empirical, and data are insufficient to indicate the superiority of a surgical or non-surgical approach to managing patients with subclinical Cushing's syndrome.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / drug therapy. Adenoma / therapy. Animals. Humans. Pheochromocytoma / diagnosis. Pheochromocytoma / therapy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500766.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 46
  •  go-up   go-down


59. Wang C, Zhou XG: [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Apr;35(4):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of CDX2 immunostaining in diagnosis of gastrointestinal adenocarcinoma].
  • OBJECTIVE: To study the expression of CDX2 in normal and tumor tissues, and to evaluate the value of CDX2 immunostaining in the diagnosis of gastrointestinal adenocarcinoma.
  • RESULTS: CDX2 was strongly expressed in surface epithelium of 13 samples of normal intestine and in ductal epithelium of 8 samples of normal pancreas, as well as in 47 samples (92.2%) of colonic adenocarcinoma and 58 samples (66.9%) of gastric adenocarcinoma.
  • The positivity rates were as follows: ovarian mucinous adenocarcinoma 15.6% (10/64), pancreatic cancer 33.3% (3/9), thyroid cancer 27.3% (3/11) and extrahepatic biliary cancer 25% (4/16).
  • On the other hand, primary tumors of breast, prostate, kidney, adrenal and liver were negative for CDX2.
  • CONCLUSIONS: CDX2 is expressed mainly in normal epithelium of intestinal tract and small pancreatic ducts, as well as in primary adenocarcinoma of gastrointestinal tract.
  • CDX2 may thus play an important role in distinguishing primary non-intestinal adenocarcinoma from metastatic adenocarcinoma of gastric or colorectal primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastrointestinal Neoplasms / diagnosis. Homeodomain Proteins / metabolism
  • [MeSH-minor] Colonic Neoplasms / diagnosis. Colonic Neoplasms / metabolism. Female. Gastrointestinal Tract / chemistry. Gastrointestinal Tract / pathology. Humans. Immunohistochemistry. Male. Stomach Neoplasms / diagnosis. Stomach Neoplasms / metabolism. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776981.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


60. Djajadiningrat-Laanen SC, Galac S, Cammelbeeck SE, van Laar KJ, Boer P, Kooistra HS: Urinary aldosterone to creatinine ratio in cats before and after suppression with salt or fludrocortisone acetate. J Vet Intern Med; 2008 Nov-Dec;22(6):1283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The endocrine diagnosis of primary hyperaldosteronism in cats currently is based on an increased plasma aldosterone to renin ratio, which has several disadvantages for use in veterinary practice.
  • In the cat with an aldosterone-producing adrenocortical carcinoma, the basal UACR and the UACR after fludrocortisone administration were 32 x 10(-9) and 36 x 10(-9), respectively.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Using the UACR for an oral fludrocortisone suppression test may be useful for the diagnosis of primary hyperaldosteronism in cats.

  • MedlinePlus Health Information. consumer health - Creatinine.
  • Hazardous Substances Data Bank. FLUDROCORTISONE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775055.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 451W47IQ8X / Sodium Chloride; 4964P6T9RB / Aldosterone; AYI8EX34EU / Creatinine; U0476M545B / Fludrocortisone
  •  go-up   go-down


61. Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, Beuschlein F, Willenberg HS, Hahner S, Saeger W, Bertherat J, Allolio B, Fassnacht M: High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab; 2010 Oct;95(10):E161-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
  • CONTEXT: No immunohistochemical marker has been established to reliably differentiate adrenocortical tumors from other adrenal masses.
  • We hypothesized that expression of steroidogenic factor-1 (SF-1), a transcription factor involved in adrenal development, is of value for the differential diagnosis of adrenal masses and predicts prognosis in adrenocortical carcinoma (ACC).
  • PATIENTS AND METHODS: SF-1 protein expression was assessed by immunohistochemistry on tissue samples from 167 ACC, 52 adrenocortical adenomas (ACA), six normal adrenal glands, six normal ovaries and 73 neoplastic nonsteroidogenic tissues.
  • In addition, SF-1 mRNA expression was present in all 91 analyzed adrenocortical tumors.
  • CONCLUSION: SF-1 is a highly valuable immunohistochemical marker to determine the adrenocortical origin of an adrenal mass with high sensitivity and specificity.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis. Steroidogenic Factor 1 / genetics
  • [MeSH-minor] Adult. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Predictive Value of Tests. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20660055.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NR5A1 protein, human; 0 / Steroidogenic Factor 1
  •  go-up   go-down


62. Lahera Vargas M, da Costa CV: [Prevalence, etiology and clinical findings of Cushing's syndrome]. Endocrinol Nutr; 2009 Jan;56(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prevalencia, etiología y cuadro clínico del síndrome de Cushing.
  • Cushing's disease is the most frequent cause of endogenous Cushing's syndrome, which is 5 or 6 times more frequent than adrenal Cushing's syndrome, with an incidence of between 1.2 and 2.4 cases per million inhabitants per year.
  • Cushing's disease is 3-8 times higher in women than in men.
  • The frequency of adrenal tumors is 3 times higher in women, while that of Cushing's syndrome due to adrenal tumors is 3-5 times higher.
  • Age at diagnosis of Cushing's syndrome varies according to the etiology.
  • Most cases of Cushing's disease are due to a pituitary adenoma, although the tumor may not be visible on the available imaging techniques.
  • ACTH-independent Cushing's syndrome is found in 20% of cases and is most frequently due to adenomas (10%) or adrenal carcinomas (8).
  • Both familial and sporadic forms exist: the familial form, or Carney complex, and ACTH-independent bilateral macronodular hyperplasia, in which the size of the adrenal glands is considerably enlarged.
  • [MeSH-minor] ACTH Syndrome, Ectopic / complications. Adenoma / complications. Adenoma / secretion. Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / secretion. Carcinoma / complications. Carcinoma / secretion. Cardiovascular Diseases / epidemiology. Diabetes Mellitus / epidemiology. Female. Glucocorticoids / adverse effects. Humans. Hydrocortisone / secretion. Hyperplasia. Incidence. Male. Phenotype. Pituitary ACTH Hypersecretion / complications. Pituitary Neoplasms / complications. Pituitary Neoplasms / secretion. Prevalence. Risk

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627706.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Glucocorticoids; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 59
  •  go-up   go-down


63. Gasilionis V, Ersahin C, Gabram S, Bova D, Branch J, Rajan P: Adrenal cortical carcinoma metastatic to the breast. J Clin Pathol; 2006 May;59(5):546-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal cortical carcinoma metastatic to the breast.
  • A 56 year old woman was diagnosed with adrenal cortical carcinoma in May 2003, for which she underwent left radical adrenalectomy.
  • A diagnosis of metastatic adrenal cortical carcinoma was made on core biopsy.
  • Subsequently, the patient underwent a lumpectomy of the mass, which confirmed the diagnosis.
  • To our knowledge, this is the first case report of adrenal cortical carcinoma metastatic to the breast.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Breast Neoplasms / secondary. Carcinoma / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1982 Jul;144(2):309-12 [7089284.001]
  • [Cites] J Clin Pathol. 1988 Feb;41(2):171-2 [2832451.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1981 Jul;89(4):251-6 [7315321.001]
  • [Cites] J Pediatr Surg. 1994 Jan;29(1):48-51 [8120761.001]
  • [Cites] J Am Coll Surg. 1994 Jul;179(1):49-53 [8019724.001]
  • [Cites] J Surg Oncol. 1991 Oct;48(2):112-6 [1921396.001]
  • (PMID = 16644887.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860300
  •  go-up   go-down


64. Fassnacht M, Kreissl MC, Weismann D, Allolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther; 2009 Jul;123(1):117-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration.
  • This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor.
  • Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma).
  • These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases.
  • First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Drug Design. Endocrine Gland Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374919.001).
  • [ISSN] 1879-016X
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Protein Kinase Inhibitors
  • [Number-of-references] 438
  •  go-up   go-down


65. Nishikawa T, Saito J, Omura M: [Medical treatment for Cushing's syndrome]. Nihon Rinsho; 2008 Jan;66(1):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is well known that the development of the microvascular disease of various organs such as the heart and kidney, in patients with diabetes mellitus, hyperlipidemia and hypertension of which disorders are frequently associated with Cushing's syndrome.
  • Thus, we should treat Cushing's syndrome as soon as possible, since many complications, including cardiovascular diseases and infections, will soon occur when the definite diagnosis is delayed.
  • Medical adrenalectomy is achieved by using with mitotane which is usually used for adrenocortical cancer.
  • We commonly treat the patients with Cushing's syndrome due to adrenal tumor and pituitary or ectopic ACTH producing tumor by using metyrapone which mainly inhibits 11-hydroxylase.
  • Metyrapone is also recommended to treat the patients who are not well differentiated Cushing's disease from ectopic ACTH syndrome.
  • Replacement therapy with hydrocortisone should be considered if adrenal failure will occur during treatment with those drugs.

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. AMINOGLUTETHIMIDE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18186263.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0O54ZQ14I9 / Aminoglutethimide; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; R9400W927I / Ketoconazole; ZS9KD92H6V / Metyrapone
  • [Number-of-references] 6
  •  go-up   go-down


66. Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd: Adrenocortical carcinoma: the influence of large vessel extension. Surgery; 2010 Dec;148(6):1057-64; discussion 1064
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: the influence of large vessel extension.
  • BACKGROUND: The impact of large vessel extension (LVE) as a prognostic factor for adrenocortical carcinoma (ACC) is not fully understood.
  • LVE was defined as vascular wall invasion or intraluminal extension of the neoplasm into the inferior vena cava or renal vein.
  • RESULTS: Multivariable regression analysis showed a significant association for decreased survival with Stage III and IV disease and LVE.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Renal Veins / pathology. Vena Cava, Inferior / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 21134533.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretagogin was strongly expressed in the cytosol and the nucleus of 19 well-differentiated neuroendocrine carcinoids and carcinoid metastases, as well as in neuroendocrine tumors from the lung, pancreas and adrenal gland.
  • Combined immunohistochemical analysis of secretagogin and FK506-binding protein 65, a protein de novo synthesized in adenocarcinomas, distinguished well-differentiated carcinoids, adenocarcinoids and undifferentiated carcinomas.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


68. Goldschneider KR, Racadio JM, Weidner NJ: Celiac plexus blockade in children using a three-dimensional fluoroscopic reconstruction technique: case reports. Reg Anesth Pain Med; 2007 Nov-Dec;32(6):510-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One carried the diagnosis of chronic pancreatitis, one abdominal pain and gastrointestinal dysmotility, the other adrenocortical carcinoma.
  • [MeSH-minor] Adrenal Cortex Neoplasms / complications. Adult. Carcinoma / complications. Child. Child, Preschool. Cystic Fibrosis / complications. Fatal Outcome. Gastrointestinal Motility / drug effects. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Mitochondrial Diseases / complications. Pain / drug therapy. Pain / etiology. Palliative Care. Pancreatitis / complications

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035298.001).
  • [ISSN] 1098-7339
  • [Journal-full-title] Regional anesthesia and pain medicine
  • [ISO-abbreviation] Reg Anesth Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M: Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol; 2010 Apr;17(4):337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
  • OBJECTIVES: To analyze the clinical effects of flutamide as a second-line anti-androgen for combined androgen blockade in patients with castration-resistant prostate cancer (CRPC) initially treated with bicalutamide as a first-line anti-androgen.
  • Furthermore, adrenal androgen levels in a medium of adrenal cancer cell line were also measured.
  • In vitro, 3 micromol/L flutamide suppressed DHEA, androstenedione and androstenediol synthesis compared with bicalutamide in a medium of adrenal cancer cell line.
  • CONCLUSIONS: Our data show that flutamide suppresses the adrenal androgens in comparison with bicalutamide.
  • Metabolites from adrenal androgens contribute to the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Androgens / blood. Flutamide / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Glands / secretion. Aged. Aged, 80 and over. Cell Line, Tumor. Humans. Male. Orchiectomy. Prognosis. Salvage Therapy


70. Shen WT, Sturgeon C, Duh QY: From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol; 2005 Mar 1;89(3):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors.
  • In this article we review the management of benign and malignant adrenal tumors, with an emphasis on oncologic concerns.
  • Concise, logical guidelines for the diagnosis and operative treatment of incidentalomas, aldosteronomas, adrenal Cushing syndrome, virilizing and feminizing adrenal tumors, isolated adrenal metastases, and adrenocortical carcinoma are provided.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Laparoscopy
  • [MeSH-minor] Adrenal Gland Neoplasms / radiography. Adrenal Gland Neoplasms / secondary. Adrenocorticotropic Hormone / blood. Aldosterone / blood. Cushing Syndrome / diagnosis. Humans. Incidental Findings. Magnetic Resonance Imaging. Radiography, Abdominal. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15719374.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 4964P6T9RB / Aldosterone; 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 32
  •  go-up   go-down


71. Lacroix A: Approach to the patient with adrenocortical carcinoma. J Clin Endocrinol Metab; 2010 Nov;95(11):4812-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Approach to the patient with adrenocortical carcinoma.
  • Adrenocortical cancer (ACC) is a rare and often aggressive malignancy that requires multidisciplinary expertise for optimal management.
  • Thorough imaging and endocrine evaluations can identify the majority of ACCs amongst adrenal tumors; however, some smaller ACCs are better identified using fluorodeoxyglucose-positron emission tomography/computed tomography scan.
  • Histopathology is important for diagnosis, but immunohistochemistry markers and gene profiling of the resected tumor may become superior to current staging systems to stratify prognosis.
  • Some retrospective studies indicate that adjuvant mitotane therapy prolongs disease-free survival, leading several centers to recommend its administration; prospective studies are under way to provide future evidence-based recommendations.
  • For metastatic disease, combination chemotherapy should be administered, if possible, in the context of multicenter collaborative research protocols.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Disease Progression. Female. Humans. Prognosis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21051577.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Breen MS, Breen M, Terasaki N, Yamazaki M, Conolly RB: Computational model of steroidogenesis in human H295R cells to predict biochemical response to endocrine-active chemicals: model development for metyrapone. Environ Health Perspect; 2010 Feb;118(2):265-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An in vitro steroidogenesis assay using the human adrenocortical carcinoma cell line H295R is being evaluated as a possible screening assay to detect and assess the impact of endocrine-active chemicals (EACs) capable of altering steroid biosynthesis.
  • OBJECTIVES: The goal of this study was to develop a mechanistic computational model of the metabolic network of adrenal steroidogenesis to estimate the synthesis and secretion of adrenal steroids in human H295R cells and their biochemical response to steroidogenesis-disrupting EAC.
  • METHODS: We developed a deterministic model that describes the biosynthetic pathways for the conversion of cholesterol to adrenal steroids and the kinetics for enzyme inhibition by metryrapone (MET), a model EAC.
  • A sensitivity analysis indicated the parameter uncertainties and identified transport and metabolic processes that most influenced the concentrations of primary adrenal steroids, aldosterone and cortisol.
  • [MeSH-major] Adrenal Glands / drug effects. Endocrine Disruptors / pharmacology. Metyrapone / pharmacology. Steroids / metabolism
  • [MeSH-minor] Cell Line, Tumor. Computational Biology / methods. Humans. Models, Theoretical

  • Hazardous Substances Data Bank. METYRAPONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Phys Lipids. 2000 Mar;105(1):9-29 [10727111.001]
  • [Cites] Am J Physiol. 1980 Jul;239(1):R184-95 [7396035.001]
  • [Cites] J Steroid Biochem Mol Biol. 2000 Dec 31;75(4-5):229-36 [11282276.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jul 1;182(1):44-54 [12127262.001]
  • [Cites] Neuro Endocrinol Lett. 2002 Jul;23 Suppl 2:43-7 [12163847.001]
  • [Cites] J Clin Invest. 2002 Oct;110(7):891-8 [12370264.001]
  • [Cites] J Appl Toxicol. 2003 Mar-Apr;23(2):81-7 [12666151.001]
  • [Cites] Toxicol Sci. 2003 Aug;74(2):245-52 [12730617.001]
  • [Cites] Toxicol Sci. 2004 Jan;77(1):151-7 [14600281.001]
  • [Cites] Science. 1986 Apr 4;232(4746):34-47 [3513311.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):295-318 [3061784.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5488-96 [2386954.001]
  • [Cites] Mol Endocrinol. 1993 Mar;7(3):423-33 [8387159.001]
  • [Cites] Mol Cell Endocrinol. 1994 Apr;100(1-2):45-50 [8056157.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21604-13 [8702948.001]
  • [Cites] J Endocrinol. 1997 Feb;152(2):159-66 [9071972.001]
  • [Cites] Environ Health Perspect. 1998 Apr;106 Suppl 2:577-82 [9599705.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Apr-Jun;69(1-6):131-41 [10418987.001]
  • [Cites] Endocr Rev. 2004 Dec;25(6):947-70 [15583024.001]
  • [Cites] Reprod Toxicol. 2005 Jan-Feb;19(3):395-409 [15686873.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2531-8 [15774561.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Aug;96(3-4):259-70 [15985365.001]
  • [Cites] Endocrinology. 2006 Jun;147(6 Suppl):S25-32 [16690802.001]
  • [Cites] Environ Health Perspect. 2006 Apr;114 Suppl 1:106-14 [16818255.001]
  • [Cites] Toxicol Sci. 2006 Nov;94(1):3-21 [16807284.001]
  • [Cites] Annu Rev Cell Dev Biol. 2006;22:129-57 [16753029.001]
  • [Cites] Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305 [16935330.001]
  • [Cites] J Appl Toxicol. 2006 Nov-Dec;26(6):484-92 [17080404.001]
  • [Cites] J Appl Toxicol. 2007 Mar-Apr;27(2):103-15 [17265431.001]
  • [Cites] Ann Biomed Eng. 2007 Jun;35(6):970-81 [17436109.001]
  • [Cites] Ecotoxicol Environ Saf. 2007 Sep;68(1):20-32 [17449096.001]
  • [Cites] Anal Bioanal Chem. 2008 Jan;390(1):287-91 [17957359.001]
  • [Cites] J Appl Toxicol. 2008 Nov;28(8):1045-53 [18626888.001]
  • [Cites] Environ Toxicol. 2009 Oct;24(5):513-21 [19161236.001]
  • [ErratumIn] Environ Health Perspect. 2011 Jan;119(1):A11
  • (PMID = 20123619.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Endocrine Disruptors; 0 / Steroids; ZS9KD92H6V / Metyrapone
  • [Other-IDs] NLM/ PMC2831928
  •  go-up   go-down


73. Oskarsson A, Ullerås E, Plant KE, Hinson JP, Goldfarb PS: Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol; 2006 Nov-Dec;26(6):484-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro.
  • The focus on the refinement, reduction and replacement of animal use in toxicity testing requires the development of cell-based systems that mimic the effects of xenobiotics in human tissues.
  • The human adrenocortical carcinoma cell line, H295R, has been proposed as a model for studies on adrenal steroidogenesis and its disruption.
  • In this study, expression profiles for nine adrenal steroidogenic genes were characterized in H295R cells using real-time RT-PCR.
  • The transcript profile from H295R cells in the presence and absence of forskolin was compared with the transcript profile from human adrenal glands.
  • The gene expression pattern observed in the forskolin-treated H295R cells was more similar to that in the human adrenal gland, than the expression pattern in untreated cells.
  • To examine H295R cells as a possible in vitro system for the assessment of adrenal disruption using molecular endpoints, the insecticide lindane (gamma-hexachlorocyclohexane) was used.
  • In vivo, lindane has been shown to inhibit testicular, ovarian and adrenal steroidogenesis.
  • It was demonstrated that lindane reduced cortisol secretion, downregulated the expression of a subset of the genes encoding steroidogenic enzymes and repressed transcriptional activation of the steroidogenic acute regulatory protein (StAR) gene promoter.
  • Thus the H295R cell line provides a good in vitro system for the analysis of the human adrenal steroidogenic pathway at the level of hormone production and gene expression.
  • This in vitro test can be used for the rapid detection of adrenal endocrine disruption and as a tool for mechanistic studies.
  • [MeSH-major] Adrenal Cortex / drug effects. Adrenal Cortex Hormones / biosynthesis. Gene Expression Regulation / drug effects. Insecticides / toxicity. Lindane / toxicity
  • [MeSH-minor] Cell Proliferation / drug effects. Cells, Cultured. Colforsin / pharmacology. Humans. Hydrocortisone / secretion. Phosphoproteins / genetics. Promoter Regions, Genetic. Steroid 11-beta-Hydroxylase / genetics. Sulfotransferases / genetics

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LINDANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 John Wiley & Sons, Ltd.
  • (PMID = 17080404.001).
  • [ISSN] 0260-437X
  • [Journal-full-title] Journal of applied toxicology : JAT
  • [ISO-abbreviation] J Appl Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Insecticides; 0 / Phosphoproteins; 0 / steroidogenic acute regulatory protein; 1F7A44V6OU / Colforsin; 59NEE7PCAB / Lindane; EC 1.14.15.4 / Steroid 11-beta-Hydroxylase; EC 2.8.2.- / Sulfotransferases; EC 2.8.2.2 / alcohol sulfotransferase; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


74. Guerrero MA, Kebebew E: Adrenocortical carcinoma and synchronous malignancies. J Cancer; 2010;1:108-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma and synchronous malignancies.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is an aggressive tumor that accounts for 0.02% of all reported cancers.
  • ACC commonly arises in a sporadic manner, but may also manifest as part of a familial syndrome.
  • Regardless of the setting, ACC rarely arises concurrent with other malignant tumors.
  • METHODS: In this report we describe a 32-year-old woman who on work-up for abnormal vaginal bleeding was diagnosed with synchronous uterine adenocarcinoma, ovarian adenocarcinoma and ACC.
  • We also provide a literature review of the past 20 years to identify other patients with ACC and synchronous malignant tumors, and those with familial syndromes associated with an increased risk of developing ACC.
  • RESULTS AND CONCLUSIONS: To our knowledge this is the first report of a patient with synchronous malignant tumors of the uterus, ovary and adrenal gland.
  • Review of the literature revealed only 5 other cases in which a patient had concurrent ACC and malignant tumors in other organs.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842232.001).
  • [ISSN] 1837-9664
  • [Journal-full-title] Journal of Cancer
  • [ISO-abbreviation] J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Other-IDs] NLM/ PMC2938073
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / Ovarian cancer / Synchronous malignancies / Uterine cancer / and Hereditary syndrome
  •  go-up   go-down


75. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • A single organ was the dominant source of metastases in 7 sites: axillary lymph node from the breast (97%), intestinal lymph node from the colon (84%), thoracic lymph node from the lung (66%), brain from the lung (64%), mediastinal lymph node from the lung (62%), supraclavicular lymph node from the breast (51%), and adrenal gland from the lung (51%).
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Tan HS, Thai AC, Nga ME, Mukherjee JJ: Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome. Ann Acad Med Singapore; 2005 Apr;34(3):271-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of ipsilateral adrenocortical carcinoma sixteen years after resection of an adrenal tumour causing Cushing's syndrome.
  • INTRODUCTION: At times, it may be difficult to differentiate early stage, low-grade adrenocortical carcinoma from benign adrenal adenoma.
  • CLINICAL PICTURE: A 53-year-old lady underwent right adrenalectomy for a 4-cm adrenocortical tumour causing Cushing's syndrome.
  • Histology revealed an adrenocortical adenoma.
  • Sixteen years later, she presented with a 14-cm adrenal tumour, again on the right side.
  • Histology confirmed adrenocortical carcinoma.
  • OUTCOME: She died of metastatic disease 17 months later.
  • CONCLUSIONS: This case highlights the importance of long-term, systematic follow-up of patients treated for benign adrenal adenomas, especially if the tumour size exceeds 4 cm.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Cushing Syndrome / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adrenocortical Adenoma / pathology. Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged


77. Barrisford GW, Sartor O, Richie JP: Solitary adrenal metastatic lesion in a patient with a history of prostate cancer. Clin Genitourin Cancer; 2009 Jan;7(1):64-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary adrenal metastatic lesion in a patient with a history of prostate cancer.
  • Prostate cancer is the most commonly diagnosed malignancy among American men.
  • Although prostate cancer-related death approximates only 3%, advanced disease can become widely disseminated.
  • Metastatic disease is often found in a number of common sites.
  • We report the uncommon presentation of a solitary adrenal lesion treated with surgical resection.
  • [MeSH-major] Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Prostatic Neoplasms / pathology


78. Karim RZ, Wills EJ, McCarthy SW, Scolyer RA: Myxoid variant of adrenocortical carcinoma: report of a unique case. Pathol Int; 2006 Feb;56(2):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid variant of adrenocortical carcinoma: report of a unique case.
  • Myxoid variant of adrenocortical carcinomas (ACC) are rare, there being only 11 cases in the literature to date.
  • Reported herein are the findings of a case, which in contrast to all previously reported myxoid ACC, was devoid of typical non-myxoid areas.
  • The patient was a 61-year-old man in whom a left adrenal mass was detected during investigation of Cushing's syndrome.
  • The adrenal was replaced by malignant cells and expanses of myxoid material.
  • The ultrastructural features of the cells were typical of adrenal cortical differentiation.
  • The differential diagnosis of myxoid ACC includes extraskeletal myxoid chondrosarcoma, chordoma, myxoid adenocarcinoma, myxoma, lipomatous tumors, nerve sheath tumors, smooth muscle tumors, gastrointestinal stromal tumor and other sarcomas.
  • The presence of myxoid material in a retroperitoneal lesion raises a broad differential diagnosis in which myxoid adrenocortical neoplasms should be included.
  • Clinicoradiological correlation may be helpful, but special stains, immunohistochemistry and ultrastructural examination may be necessary to establish the diagnosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Antigens, Neoplasm. Chordoma / diagnosis. Chordoma / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. MART-1 Antigen. Male. Microscopy, Electron. Middle Aged. Myxoma / diagnosis. Myxoma / pathology. Neoplasm Proteins / analysis. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Retroperitoneal Neoplasms / diagnosis. Retroperitoneal Neoplasms / pathology. Synaptophysin / analysis. Vimentin / analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445821.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / Synaptophysin; 0 / Vimentin
  •  go-up   go-down


79. Osman Y, El-Mekresh M, Gomha AM, Mohsen T, Taha N, Hussein N, Eraky I: Percutaneous adrenal biopsy for indeterminate adrenal lesion: complications and diagnostic accuracy. Urol Int; 2010;84(3):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous adrenal biopsy for indeterminate adrenal lesion: complications and diagnostic accuracy.
  • PURPOSE: To critically analyze the role, accuracy and safety of percutaneous adrenal biopsy for indeterminate adrenal lesions.
  • MATERIALS AND METHODS: Adrenal biopsies were performed in 15 among 214 patients (7%) diagnosed with adrenal masses being indeterminate on preoperative imaging.
  • There were 2 nonrepresentative biopsies that were proved to be adrenocortical carcinoma and myelolipoma after adrenalectomy.
  • Results of biopsy in the remaining 13 patients provided accurate diagnosis as proved by definitive histopathology in all but 2 in whom the final diagnosis was established as adrenocortical carcinoma while biopsy was paraganglioma in one and cortical adenoma in the other.
  • Overall sensitivity and negative predictive value of adrenal biopsy was 73.3 and 60%, respectively.
  • CONCLUSIONS: Percutaneous biopsy is a safe procedure for the diagnosis of pathologic conditions of the adrenal gland with a reasonable diagnostic aid.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20389162.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


80. Achatz MI, Hainaut P, Ashton-Prolla P: Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol; 2009 Sep;10(9):920-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The unusually high population frequency of a germline TP53 mutation (R337H) predisposing to early cancer has led to mass newborn testing for this mutation in the State of Paraná, southern Brazil.
  • Newborn screening for inherited cancer risk is complex and controversial.
  • R337H has been identified in Brazilian families with Li-Fraumeni or related syndromes predisposing to cancers in childhood (ie, brain, renal, and adrenocortical carcinomas), adolescence (ie, soft tissue and bone sarcomas), and young adulthood (ie, breast cancer).
  • R337H has also been detected in children with adrenocortical carcinoma without a documented family history of cancer.
  • The mutation is estimated to occur in about 0.3% of the population in southern Brazil and is associated with increased cancer risk throughout life.
  • Cancer patterns in families positive for R337H suggest strong genetic modifying effects, making it difficult to predict individual risk.
  • Because protocols for cancer-risk management in Li-Fraumeni or related syndromes are debatable, extreme care should prevail in predictive testing of children for R337H.
  • [MeSH-minor] Brazil / epidemiology. Genetic Predisposition to Disease / epidemiology. Genetic Predisposition to Disease / genetics. Humans. Infant, Newborn. Prevalence


81. Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J: Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res; 2010 Nov 1;16(21):5133-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
  • PURPOSE: In adrenocortical tumors (ACT), Wnt/β-catenin pathway activation can be explained by β-catenin somatic mutations only in a subset of tumors.
  • EXPERIMENTAL DESIGN: ACTs from patients with FAP and sporadic adrenocortical carcinomas (ACC) with abnormal β-catenin localization on immunohistochemistry but no somatic β-catenin mutations were studied.
  • RESULTS: Four ACTs were observed in three patients with FAP and were ACC, adrenocortical adenoma, and bilateral macronodular adrenocortical hyperplasia, all with abnormal β-catenin localization.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Gene Silencing. Genes, APC

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • (PMID = 20978149.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AMER1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Adenomatous Polyposis Coli Protein; 0 / Tumor Suppressor Proteins; 0 / beta Catenin
  •  go-up   go-down


82. Bertherat J, Coste J, Bertagna X: Adjuvant mitotane in adrenocortical carcinoma. N Engl J Med; 2007 Sep 20;357(12):1256-7; author reply 1259
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant mitotane in adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenocortical Carcinoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Humans. Patient Selection

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • (PMID = 17881760.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


83. Takahashi K, Shoji I, Shibasaki A, Kato I, Hiraishi K, Yamamoto H, Kaneko K, Murakami O, Morimoto R, Satoh F, Ito S, Totsune K: Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors. J Mol Neurosci; 2010 May;41(1):138-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.
  • Kisspeptins have also been reported to stimulate the aldosterone secretion from the adrenal cortex.
  • However, the expression of kisspeptins in human adrenal glands and adrenal tumors has not been clarified yet.
  • We, therefore, studied the presence of kisspeptin-like immunoreactivity (LI) in human adrenal glands and adrenal tumors (adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas) by radioimmunoassay and immunocytochemistry.
  • Kisspeptin-LI was detected in all the tissues examined; normal portions of adrenal glands (3.0 +/- 2.3 pmol/g wet weight, n = 21, mean +/- SD), aldosterone-producing adenomas (4.6 +/- 3.3 pmol/g wet weight, n = 10), cortisol-producing adenomas (2.7 +/- 1.4 pmol/g wet weight, n = 14), adrenocortical carcinomas (1.7 +/- 0.2 pmol/g wet weight, n = 4), and pheochromocytomas (1.8 +/- 0.8 pmol/g wet weight, n = 6).
  • Immunocytochemistry showed positive kisspeptin-immunostaining in normal adrenal glands, with stronger immunostaining found in the medulla.
  • Furthermore, positive kisspeptin-immunostaining was found in all types of adrenal tumors examined; adrenocortical adenomas, adrenocortical carcinomas, and pheochromocytomas.
  • The intensity of kisspeptin-immunostaining in these adrenal tumors was, however, not so strong as that in normal adrenal medulla.
  • The present study has shown for the first time the presence of kisspeptin-LI in adrenal glands and adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenal Glands / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetologia. 2009 May;52(5):855-62 [19221709.001]
  • [Cites] N Engl J Med. 2003 Oct 23;349(17):1614-27 [14573733.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1897-903 [15070962.001]
  • [Cites] Peptides. 1992 Jan-Feb;13(1):121-3 [1535705.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Aug;76(8):4079-83 [386355.001]
  • [Cites] Peptides. 2003 Feb;24(2):301-6 [12668216.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4671-8 [15914529.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34631-6 [11457843.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1319-28 [15020672.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1731-7 [8944003.001]
  • [Cites] Reprod Sci. 2007 Dec;14(8):836-45 [18089602.001]
  • [Cites] Peptides. 2008 May;29(5):873-80 [17686550.001]
  • [Cites] Endocr J. 2008 Mar;55(1):49-55 [18187873.001]
  • [Cites] Neurosci Lett. 1996 Jan 26;203(3):207-10 [8742029.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):140-7 [17023533.001]
  • [Cites] Peptides. 2000 Feb;21(2):251-6 [10764953.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28969-75 [11387329.001]
  • [Cites] Diabetologia. 2006 Sep;49(9):2131-5 [16826407.001]
  • [Cites] Nature. 2001 May 31;411(6837):613-7 [11385580.001]
  • [Cites] Endocrinology. 2004 Sep;145(9):4073-7 [15217982.001]
  • [Cites] Lancet. 1983 Sep 3;2(8349):540-2 [6136694.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15 [16174713.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4565-74 [15242985.001]
  • [Cites] J Neuroendocrinol. 2009 Mar;21(4):299-304 [19210293.001]
  • [Cites] J Endocrinol. 2008 Jul;198(1):175-83 [18460550.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 19898965.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KISS1 protein, human; 0 / Kisspeptins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


84. Chalasani S, Vats HS, Banerjee TK, McKenzie AK: Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. Clin Med Res; 2009 Jun;7(1-2):48-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
  • A 57-year-old white woman with metastases to lungs and liver from virilizing adrenocortical carcinoma (ACC) was treated with radical nephroadrenalectomy followed by oral mitotane 3 to 6 g/day for 5 months.
  • She developed complete response and remained free of disease for more than 25 years.
  • Stage I and II disease is curable with surgery.
  • Stage III and IV disease may benefit from mitotane orally with gradual adjustment of the dosage to a tolerable level.
  • An international study has been started by randomizing between two of the above combinations by the Collaborative Group for Adrenocortical Carcinoma Treatment.
  • [MeSH-major] Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use
  • [MeSH-minor] Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Remission Induction. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1995 Jun;172(6):1912-4; discussion 1914-5 [7778652.001]
  • [Cites] Surgery. 1991 Dec;110(6):1006-13 [1745969.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8 [10852456.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] J Endocrinol Invest. 2001 Jul-Aug;24(7):532-5 [11508789.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4452-6 [12364417.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Ann Intern Med. 1975 May;82(5):677-9 [1137262.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Eur J Surg Oncol. 1990 Dec;16(6):500-6 [2253796.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • (PMID = 19574489.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2705271
  •  go-up   go-down


85. Tyan YC, Wu HY, Su WC, Chen PW, Liao PC: Proteomic analysis of human pleural effusion. Proteomics; 2005 Mar;5(4):1062-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A composite sample was prepared by pooling pleural effusions from seven lung adenocarcinoma patients.
  • Retinoblastoma binding protein 7 is of special interest since it may play a role in the regulation of cell proliferation and differentiation.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adrenal Cortex Hormones / metabolism. Adult. Aged. Biomarkers. Cell Differentiation. Cell Proliferation. Chromatography, Liquid. Databases, Protein. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Image Processing, Computer-Assisted. Ions. Lung Neoplasms / metabolism. Male. Mass Spectrometry. Middle Aged. Peptides / chemistry. Protein Structure, Tertiary. Retinoblastoma Protein / metabolism. Silver Staining. Trypsin / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682465.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Biomarkers; 0 / Ions; 0 / Peptides; 0 / Retinoblastoma Protein; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


86. Castellano MC, Massone AR, Idiart JR: Primary pulmonary adenocarcinoma metastatic to the uvea, brain and adrenal gland in a dog. J Vet Med A Physiol Pathol Clin Med; 2006 May;53(4):194-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pulmonary adenocarcinoma metastatic to the uvea, brain and adrenal gland in a dog.
  • On necropsy, lung masses and nodules in left iris, right adrenal medulla, and brain were detected.
  • Histologically the primary tumour was diagnosed as pulmonary adenocarcinoma with predominant solid pattern.
  • Metastases to regional lymph nodes, uvea, adrenal medulla, and brain were recognized.
  • To the authors' knowledge, this is the first report of a pulmonary adenocarcinoma with metastasis to the uvea in a dog.
  • [MeSH-major] Adenocarcinoma / veterinary. Brain Neoplasms / veterinary. Dog Diseases / pathology. Lung Neoplasms / veterinary. Uveal Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16629953.001).
  • [ISSN] 0931-184X
  • [Journal-full-title] Journal of veterinary medicine. A, Physiology, pathology, clinical medicine
  • [ISO-abbreviation] J Vet Med A Physiol Pathol Clin Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Sasano H, Suzuki T, Moriya T: Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol; 2006;17(4):345-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma.
  • Discerning malignancy in resected adrenocortical neoplasms can pose diagnostic difficulty.
  • Macroscopic examination is the first important step toward diagnosis and should include accurate measurement of weight and dimension of the specimens and description of the cut surface of the tumors.
  • It is also important to sample the specimens for histological diagnosis near foci of hemorrhage and/or necrosis.
  • Histological scoring systems evaluating multiple parameters, especially the criteria of Weiss, have been shown to be reliable in differential diagnosis between adrenocortical adenoma and carcinoma.
  • A tumor is defined as adrenocortical carcinoma when three or more of the following criteria are met;.
  • The criteria are relatively straightforward and considered the most effective standard for diagnosis of adrenocortical malignancy.
  • However, great care should be taken in applying the criteria to histological evaluation of two relatively rare and peculiar adrenocortical tumors, adrenocortical oncocytoma and pediatric adrenocortical neoplasms.
  • At this juncture, ancillary biological or molecular markers are of little practical value in terms of differential diagnosis between adrenocortical adenoma and carcinoma but tumors with MIB1 or Ki-67 labeling index more than 2.5 may be considered malignant.
  • Prognostic markers of adrenocortical carcinoma have not been established other than complete respectability of the tumor.
  • It sometimes is important for surgical pathologists to differentiate adrenocortical carcinoma from metastatic malignancies of other sites.
  • An immunohistochemical evaluation of adrenal 4 binding protein (Ad4BP) or SF-1, a transcription factor of all steroidogenesis, can aid in this differential diagnosis because nuclear immunoreactivity for this transcription factor is relatively specific to steroid producing cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Adrenocortical Adenoma / diagnosis. Biomarkers, Tumor / analysis. Cell Count. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Mitotic Index. Ubiquitin-Protein Ligases / analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Dec;11(12):1165-70 [9872646.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1988;413(4):313-8 [3140475.001]
  • [Cites] Hum Pathol. 1995 Oct;26(10):1154-6 [7557951.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):867-81 [12826878.001]
  • [Cites] Arch Pathol Lab Med. 1986 Nov;110(11):1076-9 [3778125.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1561-5 [12085205.001]
  • [Cites] Diagn Cytopathol. 2000 May;22(5):299-303 [10790237.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):335-41 [11517015.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):181-5 [10025460.001]
  • [Cites] Endocr J. 1994 Oct;41(5):471-82 [7889106.001]
  • [Cites] Am J Surg Pathol. 1991 Oct;15(10 ):949-56 [1928551.001]
  • [Cites] Am J Clin Pathol. 1979 Sep;72(3):390-9 [474519.001]
  • [Cites] J Urol. 2005 Jun;173(6):2138-42 [15879867.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Am J Surg Pathol. 1989 Mar;13(3):202-6 [2919718.001]
  • [Cites] Mod Pathol. 1997 Sep;10(9):901-7 [9310953.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2194-200 [9827725.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Urology. 2001 Jan;57(1):176-82 [11164177.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Apr;6(4):386-94 [15898346.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3296-303 [8242556.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Am J Clin Pathol. 1995 Aug;104(2):161-6 [7639190.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):941-50 [11844815.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Sep;80(9):2815-21 [7673429.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:1-53 [1736241.001]
  • [Cites] Trends Endocrinol Metab. 2003 Nov;14(9):404-10 [14580759.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 17525483.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases
  • [Number-of-references] 33
  •  go-up   go-down


88. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Medical records of patients with the diagnosis of ADCC between 1990 and 2000 were reviewed.
  • Factors associated with a worse prognosis were stage of disease, nonoperative management, positive surgical margins, vascular invasion, and older age.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. de Moura Gallo CV, Azevedo E Silva Mendonça G, de Moraes E, Olivier M, Hainaut P: TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives. Mutat Res; 2005 May;589(3):192-207
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives.
  • Due to particular social and economical development, and to the impact of globalization of lifestyles, Latin America shows a superposition of cancers that are frequent in low resource countries (gastric, oesophageal squamous cell and cervical cancers) and high resource countries (cancers of breast, colon and rectum, lung and prostate).
  • Latin America thus offers opportunities for investigating the impact on changing lifestyle patterns on the occurrence of cancer.
  • At the molecular level, mutations in the tumor suppressor gene TP53 are common in many cancers and their distribution can be informative of the nature of the mutagenic mechanisms, thus giving clues to cancer etiology and molecular pathogenesis.
  • In this review, we discuss current trends on cancer occurrence in Latin American countries, and we review the literature available on TP53 mutations and polymorphisms in patients from Latin America.
  • Recently, a characteristic TP53 mutation at codon 337 (R337H) has been identified in the germline of children with adrenocortical carcinoma in Southern Brazil.
  • Further and better focused analyses of TP53 mutation patterns in the context of epidemiological studies, should help to improve our understanding of cancer etiology in order to develop appropriate health policies and public health programs in Latin America.
  • [MeSH-major] Genes, p53. Genetic Markers. Genetic Predisposition to Disease. Life Style. Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15878142.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Number-of-references] 100
  •  go-up   go-down


90. Nunes ML, Rault A, Teynie J, Valli N, Guyot M, Gaye D, Belleannee G, Tabarin A: 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg; 2010 Jul;34(7):1506-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
  • BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been proposed for the evaluation of adrenal tumors.
  • However, only scarce data are available to evaluate its usefulness for the identification of primary adrenal carcinomas in patients with no previous history of cancer and equivocal tumors on computed tomography (CT) scan.
  • Twenty-three consecutive patients without previous history of cancer investigated for adrenal tumors without features of benign adrenocortical adenoma on CT scan but no obvious ACC underwent 18F-FDG PET.
  • The ratio of maxSUV adrenal tumor on maxSUV liver (adrenal/liver maxSUV ratio) during 18F-FDG PET was compared to Weiss pathological criteria.
  • RESULTS: Seventeen patients had an adrenal adenoma, 2 had small size adrenal carcinomas (<5 cm), 1 had an angiosarcoma, and 3 had noncortical benign lesions.
  • An adrenal/liver maxSUV ratio above 1.6 provided 100% sensitivity, 90% specificity, and 100% negative predictive value for the diagnosis of malignant tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnostic imaging. Adrenal Gland Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adrenocortical Adenoma / diagnostic imaging. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5 [16670169.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):871-7 [15572420.001]
  • [Cites] Radiology. 2005 Feb;234(2):479-85 [15671003.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2018-25 [18566816.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):637-44 [10690869.001]
  • [Cites] Cancer. 2009 Jan 15;115(2):243-50 [19025987.001]
  • [Cites] J Nucl Med. 2001 Jun;42(6):884-92 [11390552.001]
  • [Cites] Radiology. 2006 Mar;238(3):970-7 [16505394.001]
  • [Cites] Int J Clin Pract. 2007 May;61(5):802-9 [17343665.001]
  • [Cites] J Clin Endocrinol Metab. 2009 May;94(5):1713-22 [19190108.001]
  • (PMID = 20396886.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


91. Barlaskar FM, Hammer GD: The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord; 2007 Dec;8(4):343-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The molecular genetics of adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Genetic Predisposition to Disease / genetics

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Feb;51(3):231-43 [11407595.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Mar;90(3):1819-29 [15613424.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7622-7 [16140927.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] Mol Cell Endocrinol. 2007 Feb;265-266:10-6 [17240045.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22429-33 [16793760.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):370-3 [17671971.001]
  • [Cites] Neoplasia. 2000 May-Jun;2(3):208-25 [10935507.001]
  • [Cites] Endocrinology. 1999 Apr;140(4):1537-43 [10098485.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] J Natl Cancer Inst. 1989 Apr 5;81(7):518-23 [2564050.001]
  • [Cites] Cell Regul. 1990 Jan;1(2):197-213 [1966041.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Mol Endocrinol. 2003 Apr;17(4):507-19 [12554773.001]
  • [Cites] Eur J Endocrinol. 2005 Oct;153(4):477-87 [16189167.001]
  • [Cites] Surgery. 2000 Dec;128(6):973-82;discussion 982-3 [11114632.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):711-36 [10679640.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2559-65 [9253334.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:222-39 [12119279.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6762-7 [11559548.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] Mol Med. 2002 Dec;8(12):771-80 [12606812.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):521-31 [12547710.001]
  • [Cites] Cell. 2006 Dec 29;127(7):1323-34 [17182091.001]
  • [Cites] Eur J Endocrinol. 2006 Apr;154(4):587-98 [16556722.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):460-84 [8521790.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2194-200 [9827725.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3145-55 [8242539.001]
  • [Cites] J Endocrinol. 2001 Nov;171(2):209-15 [11691640.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] Nat Struct Biol. 2002 Jan;9(1):12-6 [11753428.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] BMC Dev Biol. 2007 May 21;7:53 [17517131.001]
  • [Cites] World J Surg. 2001 Jul;25(7):927-33 [11572034.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9 [10760284.001]
  • [Cites] J Genet Hum. 1964 Sep;13:223-32 [14231762.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S33-43 [17259557.001]
  • [Cites] Nature. 1997 May 8;387(6629):151-8 [9144284.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26572-9 [12732619.001]
  • [Cites] Cytogenet Genome Res. 2006;113(1-4):188-93 [16575179.001]
  • [Cites] ANZ J Surg. 2003 Sep;73(9):727-38 [12956790.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):600-8 [17234769.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2005 Aug 15;137C(1):12-23 [16010676.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1317-24 [9141510.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] Horm Metab Res. 2004 Jun;36(6):397-405 [15241731.001]
  • [Cites] Trends Endocrinol Metab. 2003 Nov;14(9):404-10 [14580759.001]
  • [Cites] Am J Hum Genet. 1951 Jun;3(2):167-76 [14902760.001]
  • [Cites] Surgery. 2005 Dec;138(6):1087-94 [16360395.001]
  • (PMID = 17934868.001).
  • [ISSN] 1389-9155
  • [Journal-full-title] Reviews in endocrine & metabolic disorders
  • [ISO-abbreviation] Rev Endocr Metab Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CDKN1C protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / Tumor Suppressor Protein p53; 67763-97-7 / Insulin-Like Growth Factor II
  • [Number-of-references] 56
  •  go-up   go-down


92. Kayton ML: Pulmonary metastasectomy in pediatric patients. Thorac Surg Clin; 2006 May;16(2):167-83, vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By examining tumor types individually, however, it is seen that certain histologies (adrenocortical carcinoma, alveolar soft part sarcoma, osteosarcoma) mandate surgical metastasectomy for patient survival.
  • In the case of still other types of tumor (neuroblastoma, differentiated thyroid cancer, rhabdomyosarcoma), metastasectomy is seldom performed except in highly unusual situations.
  • [MeSH-minor] Biopsy. Child. Humans. Infant. Minimally Invasive Surgical Procedures. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / secondary. Neoplasms, Complex and Mixed / surgery. Neoplasms, Glandular and Epithelial / diagnosis. Neoplasms, Glandular and Epithelial / secondary. Neoplasms, Glandular and Epithelial / surgery. Pulmonary Surgical Procedures. Sarcoma / diagnosis. Sarcoma / secondary. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805206.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


93. Qin ZK, Zhou FJ, Dai YP, Chen W, Hou JH, Han H, Liu ZW, Yu SL, Zhang DZ, Yang JA: [Expression and clinical significance of survivin and PTEN in adrenal tumors]. Ai Zheng; 2007 Oct;26(10):1143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of survivin and PTEN in adrenal tumors].
  • BACKGROUND & OBJECTIVE: Since the histomorphology of adrenal tumor is very special, it is difficult to assess the malignancy of the tumors.
  • This study was to explore the expression and clinical significance of Survivin and PTEN proteins in adrenal tumors.
  • METHODS: The expression of Survivin and PTEN in 116 specimens of adrenal tumors, including 39 cases of cortex adenoma, 22 cases of cortex adenocarcinoma, 35 cases of pheochromocytoma, and 20 cases of malignant pheochromocytoma, were detected by LSAB immunohistochemistry.
  • The expression intensity of Survivin was correlated to that of PTEN in adrenal tumors (r=-0.486, P<0.05).
  • The expression intensity of Survivin and PTEN in adrenal tumors were not related to patient's age, sex, tumor position, and so on (P>0.05).
  • The expression intensity of Survivin was significantly lower in adrenal cortex adenoma than in adrenal cortex adenocarcinoma (P<0.05), and was significantly lower in pheochromocytoma than in malignant pheochromocytoma (P<0.05).
  • The expression intensity of PTEN was related to the differentiation of adrenal tumor.
  • The expression intensity of PTEN was significantly higher in adrenal cortex adenoma than in adrenal cortex adenocarcinoma (P<0.05), and was significantly higher in pheochromocytoma than in malignant pheochromocytoma (P<0.05).
  • The expression of Survivin protein and PTEN protein was correlated to the prognosis of adrenal cortex adenocarcinoma and malignant pheochromocytoma: the higher the expression intensity of Survivin protein and the lower the expression intensity of PTEN protein, the worse the patient's prognosis (P<0.05).
  • CONCLUSION: The expression of Survivin and PTEN proteins are closely related to the prognosis of adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Adrenocortical Carcinoma / metabolism. Microtubule-Associated Proteins / metabolism. PTEN Phosphohydrolase / metabolism. Pheochromocytoma / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927889.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


94. Matsumoto K, Egawa S, Satoh T, Okuno N, Kaseda S, Baba S: Thoracoscopic transdiaphragmatic adrenalectomy for isolated locally recurrent adrenal carcinoma. Int J Urol; 2005 Dec;12(12):1055-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thoracoscopic transdiaphragmatic adrenalectomy for isolated locally recurrent adrenal carcinoma.
  • A 58-year-old man who had undergone left adrenalectomy 2 years previously for adrenocortical carcinoma was diagnosed to have a left suprarenal solid mass.
  • Thoracoscopic transdiaphragmatic excision of the tumor was conducted under the diagnosis of isolated local recurrence of adrenal carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / surgery. Thoracoscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16409610.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. Asp V, Ullerås E, Lindström V, Bergström U, Oskarsson A, Brandt I: Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells. Toxicol Appl Pharmacol; 2010 Feb 1;242(3):281-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The DDT metabolite 3-methylsulfonyl-DDE (3-MeSO(2)-DDE) has been proposed as a lead compound for an improved adrenocortical carcinoma (ACC) treatment.
  • ACC is a rare malignant disorder with poor prognosis, and the current pharmacological therapy o,p'-DDD (mitotane) has limited efficacy and causes severe adverse effects.
  • 3-MeSO(2)-DDE is bioactivated by cytochrome P450 (CYP) 11B1 in mice and causes formation of irreversibly bound protein adducts, reduced glucocorticoid secretion, and cell death in the adrenal cortex of several animal species.
  • The results support previous indications that humans are sensitive to the adrenocorticolytic actions of 3-MeSO(2)-DDE by demonstrating protein adduct formation and cytotoxicity in the human adrenocortical cell line H295R.
  • [MeSH-major] Adrenal Cortex / drug effects. Antineoplastic Agents, Hormonal / pharmacology. DDT / metabolism. Dichlorodiphenyl Dichloroethylene / analogs & derivatives
  • [MeSH-minor] Adrenal Gland Neoplasms / drug therapy. Aldosterone / secretion. Animals. Cell Line. Dose-Response Relationship, Drug. Drug Design. Humans. Hydrocortisone / secretion. Mice. RNA, Messenger / metabolism. Species Specificity

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. DDT .
  • Hazardous Substances Data Bank. DDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19900470.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / RNA, Messenger; 4964P6T9RB / Aldosterone; 4M7FS82U08 / Dichlorodiphenyl Dichloroethylene; 62938-14-1 / 1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene; CIW5S16655 / DDT; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


96. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S: Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol; 2009 Oct;161(4):513-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?
  • OBJECTIVE: To assess the performance of current clinical recommendations for the evaluation of an adrenal incidentaloma.
  • Eligible studies were those deemed most applicable to the clinical scenario of a patient referred to an endocrinologist for assessment of an incidentally detected adrenal mass.
  • RESULTS: The prevalence of functional and malignant lesions presenting as adrenal incidentaloma was similar to that quoted in most reviews, other than a lower incidence of adrenal carcinoma (1.9 vs 4.7%) and metastases (0.7 vs 2.3%).
  • The development of functionality or malignancy during follow-up was rare (<1% becoming functional and 0.2% becoming malignant).
  • The average recommended computed tomography (CT) scan follow-up exposes each patient to 23 mSv of ionising radiation, equating to a 1 in 430 to 2170 chance of causing fatal cancer.
  • This is similar to the chance of developing adrenal malignancy during 3-year follow-up of adrenal incidentaloma.
  • CONCLUSION: Current recommendations for evaluation of adrenal incidentaloma are likely to result in significant costs, both financial and emotional, due to high false-positive rates.
  • The dose of radiation involved in currently recommended CT scan follow-up confers a risk of fatal cancer that is similar to the risk of the adrenal becoming malignant.


97. Wu M, Szporn AH, Zhang D, Wasserman P, Gan L, Miller L, Burstein DE: Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol; 2005 Oct;33(4):223-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.
  • The pathologic distinction of small cell from non-small cell-lung carcinoma is of considerable therapeutic significance.
  • In particular, the ability to distinguish poorly differentiated non-small-cell lung cancer from small-cell lung carcinoma (SCLC) is at times difficult based upon morphology alone; available immunohistochemical markers such as neuroendocrine markers are of limited utility.
  • We have demonstrated the role of p63 and thyroid transcription factor-1 (TTF-1) in the differential diagnosis of poorly differentiated squamous-cell carcinoma (PDSCC) versus SCLC, mostly in biopsy samples (Wu et al., American Journal of Clinical Pathology 2003;119:696-702).
  • Here, we examine further the utility of this panel in cytologic cell-block samples of lung cancers including both primary and metastatic cancers of pulmonary origin, and cases of nonpulmonary cancers metastatic to lung in which differential diagnoses included a lung primary.Four-micron thick sections of 30 alcohol-fixed paraffin-embedded cell blocks from 14 lung FNAs, 6 liver FNAs, 3 bronchial washings, 1 subcarinal lymph node FNA, 1 iliac lymph node FNA, 1 pelvic mass FNA, 1 neck lymph node FNA, 1 adrenal FNA, and 1 pleural effusion were deparaffinized and stained with monoclonal antibodies reactive to p63 (1:800, Santa Cruz Biotechnology) and TTF-1 (1:50, Dako).
  • All 4 primary lung adenocarcinoma cases were p63-/TTF-1+; contrasting with nonpulmonary adenocarcinomas that were all p63-/TTF-1-.
  • The panel of p63 and TTF-1 appears to be useful in the diagnostic evaluation of cytologic cell-block samples of pulmonary malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor. Carcinoma, Small Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Lung Neoplasms / diagnosis. Nuclear Proteins. Phosphoproteins. Trans-Activators. Transcription Factors
  • [MeSH-minor] Biopsy, Fine-Needle. DNA-Binding Proteins. Diagnosis, Differential. Genes, Tumor Suppressor. Humans. Lymph Nodes / pathology. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16138374.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / thyroid nuclear factor 1
  •  go-up   go-down


98. Di Carlo I, Toro A, Sparatore F, Cordio S: Liver resection for hepatic metastases from adrenocortical carcinoma. HPB (Oxford); 2006;8(2):106-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for hepatic metastases from adrenocortical carcinoma.
  • Liver metastases from adrenocortical carcinoma are very rare and no clear indications for surgery exist.
  • All the patients submitted to hepatic resection for liver metastases from adrenal carcinoma reported in the literature (PubMed source) from 1978 to 2005 were considered for the present study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Oct;85(10):1423-7 [9782030.001]
  • [Cites] Chirurg. 1999 Apr;70(4):439-46 [10354843.001]
  • [Cites] Liver Transpl. 2000 Jan;6(1):97-101 [10648585.001]
  • [Cites] Dig Surg. 1999;16(6):459-67 [10805544.001]
  • [Cites] Langenbecks Arch Surg. 2000 Oct;385(6):393-7 [11127523.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1532-6 [11775186.001]
  • [Cites] Hepatogastroenterology. 2002 Mar-Apr;49(44):535-7 [11995490.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):343-5 [15086154.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):269-76 [15650637.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12(6):459-66 [15886903.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):421-34 [3178330.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):239-46 [3629438.001]
  • [Cites] Am J Surg. 1978 Mar;135(3):389-94 [626320.001]
  • [Cites] Surgery. 1997 Jun;121(6):625-32 [9186462.001]
  • [Cites] Oncology. 1997 Nov-Dec;54(6):490-6 [9394846.001]
  • (PMID = 18333256.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2131421
  •  go-up   go-down


99. Mezhir JJ, Song J, Piano G, Testa G, Raman J, Al-Ahmadie HA, Angelos P: Adrenocortical carcinoma invading the inferior vena cava: case report and literature review. Endocr Pract; 2008 Sep;14(6):721-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma invading the inferior vena cava: case report and literature review.
  • OBJECTIVE: To present the case of a man with a right-sided adrenocortical carcinoma that invaded the inferior vena cava and was managed by radical resection and vein patch repair.
  • The literature is reviewed for the management of adrenocortical carcinoma in conjunction with inferior vena cava invasion.
  • RESULTS: In a 34-year-old man with new-onset abdominal pain, abdominal imaging disclosed a large right adrenal mass with invasion into the inferior vena cava.
  • Laboratory values revealed that the adrenal mass was likely nonfunctional.
  • At surgical intervention with use of cardiopulmonary bypass, the mass was removed en bloc with the adrenal gland, right kidney, and the wall of the inferior vena cava, and the inferior vena cava was reconstructed with bovine pericardium.
  • Thus, this scenario should not preclude attempted curative resection in patients with adrenal cancer.
  • [MeSH-major] Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / pathology. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996792.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


100. Bussey KJ, Demeure MJ: Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment. Future Oncol; 2009 Jun;5(5):641-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
  • Adrenocortical carcinoma (ACC) is an aggressive endocrine tumor with a poor 5-year survival rate of 10-20%.
  • Although ACC is extremely rare, recent advances in genomic and expression profiling, coupled with knowledge gained from the study of the inherited syndromes that increase ACC risk, are beginning to bring together a picture of a tumor type dependent on p53, the G2/M cell cycle transition and IGF2 stimulation.
  • Nevertheless, ACC remains a heterogeneous disease.
  • Advances in treatment will depend on exploiting those pathways already implicated in ACC, along with those yet to be identified, and testing those treatments in better models of the disease than the three cell lines that currently exist and are widely available to the community.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / genetics. Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / genetics. Adrenocortical Carcinoma / therapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519204.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 73
  •  go-up   go-down






Advertisement